
ISoOR International Society of Organoid Research

INTERNATIONAL STANDARD FOR ORGANOID BIOBANKING

ISoOR–ISOB

First Edition (Version 1.2.1), 2026

First published 2025 | Revised 2026 | Updated publication: 9 November 2026



Publication Information

ISoOR-ISOB — First Edition (Version 1.2.1), 2026

First published 2025; revised 2026

Update publication date: 9 November, 2026

Copyright © 2025 by International Society of Organoid Research (ISoOR). All rights reserved.

Contact Information

International Society of Organoid Research (ISoOR)
One North Crescent, #07-02, Razer SEA HQ
Singapore, 138538
Singapore
www.isoor.org
Secretary@isoor.org

Disclaimer

The ISoOR International Standard for Organoid Biobanking (ISoOR-ISOB) establishes normative requirements and recommendations for the quality, competence, ethical conduct, and operation of organoid biobanks. Conformity with this standard requires compliance with its applicable mandatory provisions.

This standard does not replace or supersede applicable national or international laws, regulations, or ethical requirements. Organizations implementing ISoOR-ISOB remain responsible for ensuring compliance with all relevant legal and regulatory obligations.

ISoOR assumes no responsibility for decisions or actions undertaken by organizations based on the application of this standard.

Acknowledgments

ISoOR extends its sincere gratitude to the ISoOR-ISOB technical committee, sponsors and organizations that supported the development of this initiative.

We also wish to acknowledge the dedicated efforts of the ISoOR working group and all other contributors whose hard work and collaboration made this standard possible.

Table of Contents

Foreword **7**
1 Scope: **8**
2 Objectives: **9**
2.1 Quality Assurance 9
2.2 Ethical Compliance 9
2.3 Traceability and Provenance 9
2.4 Data Integrity and Security 9
2.5 Support for Organoid Applications 9
2.6 Standardization of Practices 9
2.7 Risk Management 9
2.8 Resource Management 9
2.9 Accessibility and “Equity” 9
2.10 Continuous Improvement 9
2.11 International Collaboration 9
3 Basic Criteria **10**
3.1 Overview 10
3.2 Equity 10
3.3 OB Specimens Management and Ethical Compliance 10
3.4 Traceability of Process Information 11
3.4.1 Scope of Traceability 11
3.4.2 Documentation and Recording Systems 11
3.4.3 Compliance Verification 11
3.4.4 Digital Systems for Process Traceability 11
3.4.5 Traceability in Collaborative Projects 11
3.4.6 Incident Management and Non-Compliance Reporting 11
3.5 Legal and Ethical Requirements 12
3.5.1 “Legal Ownership” of Organoids and Data 12
3.5.2 “Data Protection and Privacy” 12
3.5.3 “Access to Organoids and Data” 12
3.6 Compliance with “Intellectual Property (IP) Rights” 12
3.6.1 Intellectual Property Considerations 12
3.7 Legislative and Policy Awareness 12
3.7.1 Monitoring and Implementation of Legislative Changes 12
4 Structural Requisites **13**
4.1 Organizational Structure 13
4.2 Facilities and Infrastructure 13
4.3 Equipment and Materials 13
4.4 Information Management System 13
4.5 “Quality Management System” (QMS) 13
4.6 Personnel Competence 13
4.7 Safety and Environmental Conditions 14
4.8 Ethical Considerations 14
4.9 “Regulatory Compliance” 14
4.10 External Services and Supply Chain 14
5 Resource Criteria **15**
5.1 Overview 15
5.2 Human Resources 15
5.2.1 Competence and Skill Evaluation 15
5.2.2 Training 15
5.2.2.1 Preliminary job training 15
5.2.2.2 Quality system training 15
5.2.2.3 Job-specific training 16
5.2.2.4 Continuing education 16
5.2.2.5 “Good Laboratory Practice” (GLP) training 16
5.2.2.6 Biosafety training 16
5.2.2.7 Traceability procedures training 16
5.2.2.8 Ethical and legal compliance training 16
5.2.2.9 “Standard Operating Procedures” (SOPs) training 16
5.3 Equipment 16
5.3.1 Acquisition and Installation Process 16
5.3.2 Verification and Operation of Technical Resources 16
5.3.3 Calibration and Accuracy of Tools and Devices 16
5.3.4 Equipment Inspection, Maintenance, and Servicing 17
5.3.5 Monitoring of Equipment 17
5.3.6 Data Management and Information Management Systems 17
5.3.6.1 General 17

5.3.6.2 Governance and risk management ... 17
5.3.6.3 Data quality, metadata and provenance ... 17
5.3.6.4 Interoperability, access and sharing ... 18
5.3.6.5 System control, continuity and lifecycle management ... 18
5.3.7 Appropriate and Responsible Use of Artificial Intelligence Systems ... 19
5.3.7.1 General ... 19
5.3.7.2 Governance and accountability ... 19
5.3.7.3 Risk assessment and authorization ... 19
5.3.7.4 Validation, monitoring and lifecycle control ... 20
5.3.7.5 Human oversight, transparency and guardrails ... 21
5.3.7.6 Competence and awareness ... 21
5.4 Infrastructure and Ambient Parameters ... 21
5.5 Third-Party Operations ... 21
5.6 Laboratory Supplies, Chemicals, and other Consumables ... 22
5.6.1 Overview ... 22
5.6.2 Receipt and Storage ... 22
5.6.3 Acceptance Testing ... 22
5.6.4 Inventory Management ... 22
5.6.5 Instructions for Use ... 22
5.6.6 Adverse Incident Reporting ... 22
5.6.7 Records ... 22
5.6.8 Standardization of Reagents for Organoid Development, Transportation and Storage ... 22
5.6.8.1 General Requirements for Reagents ... 22
5.6.8.2 Biochemical Composition and Optimization ... 22
5.6.8.3 Heterogeneity and Functional Support ... 23
5.6.9 “Biochemical Consistency” ... 23
5.6.10 ECMs ... 23
5.6.10.1 Material Selection ... 23
5.6.10.2 Composition and Batch Consistency ... 23
5.6.10.2.1 Avoidance of Undefined Matrices ... 23
5.6.10.2.2 Use of Animal-Derived Products ... 23
5.6.10.2.3 Quality Control and Mitigation of Variability ... 23
5.6.10.2.4 Balancing Quality and Reproducibility ... 24
5.6.10.3 “Biocompatibility” ... 24
5.6.10.4 Mechanical and Physical Properties ... 24
5.6.10.5 Decellularized Tissue ECM ... 24
5.6.10.6 Stiffness and Elasticity of ECMs ... 24
5.6.10.7 Mechanical Pressure Exerted by ECMs ... 24
5.6.10.8 Reference-Stock ECMs for Functional Testing ... 24
5.6.10.9 Risk Assessment ... 24
6 Operational Criteria ... 25
6.1 Overview ... 25
6.2 Quality Management ... 25
6.3 “Documentation and Record Keeping” ... 25
6.4 Staff Training and Competence ... 25
6.4.1 Training Programs ... 25
6.4.2 Initial Training ... 25
6.4.3 Ongoing Professional Development ... 25
6.4.4 Refresher Courses ... 25
6.4.5 Specialized Training ... 25
6.4.6 Assessment and Certification ... 25
6.4.7 Cross-Training ... 26
6.4.8 Mentorship and Supervision ... 26
6.4.9 Continuous Learning Culture ... 26
6.4.10 Access to Resources ... 26
6.4.11 Training Records ... 26
6.5 Sample Handling ... 26
6.5.1 Sample Collection ... 26
6.5.1.1 Collection Tools ... 26
6.5.1.2 Conditions ... 26
6.5.1.3 Documentation ... 26
6.5.2 Sample Processing ... 26
6.5.2.1 Initial Processing ... 26
6.5.2.2 Handling Procedures ... 26
6.5.2.3 Processing Conditions ... 26
6.5.2.4 Sample Preservation ... 26
6.5.2.5 Receipt and Acceptance of Externally Obtained Organoid and Source Materials ... 27
6.5.3 “Organoid Quality Characterization” ... 27
6.5.3.1 Defining Quality Metrics ... 27

6.5.3.2 “Molecular Characterization” 27
6.5.3.3 Genetic Stability 27
6.5.3.4 “Functional Validation” 28
6.5.3.5 Morphological Assessment 28
6.5.4 Quality Control (QC) 28
6.5.4.1 Key elements of QC 28
6.5.4.2 Audits and Reviews 29
6.5.4.3 Corrective Actions 29
6.5.5 Alignment with Relevant Standards 29
6.6 “Metrics” 29
6.6.1 Overview 29
6.6.2 Selection of Metrics 29
6.6.3 Standardization of Measurement Methods and Audit 30
6.6.3.1 Overview 30
6.6.3.2 Inclusion of Metrics 30
6.6.3.3 Measurement Techniques 30
6.6.3.3.1 Morphological Evaluation 30
6.6.3.3.2 Functional Measurement 30
6.6.3.3.3 “Molecular Resemblance” 30
6.6.3.4 Additional Metrics 30
6.6.3.5 Validation of Data 30
6.6.3.5.1 Impact of Device Type on Quantification 30
6.6.3.5.2 Recommended Techniques and Equipment 30
6.6.3.6 Regular Audit and Review 30
6.6.4 Metrics for Quality Control and Assurance 31
6.6.5 Data Recording and Analysis 31
6.6.6 Continuous Improvement 31
6.7 Storage Conditions 31
6.7.1 Monitoring 31
6.7.2 Temperature Control 31
6.7.3 Humidity and Gas Composition 31
6.7.4 Freezing Process 31
6.7.5 “Freezing Rate” 32
6.7.5.1 Controlled Freezing Conditions 32
6.7.5.2 Freezing Protocol Documentation 32
6.7.6 Thawing Process 32
6.7.6.1 Controlled Thawing Conditions 32
6.7.6.2 Thawing Protocol Documentation 32
6.7.6.3 Post-Thaw Culture and Recovery 32
6.7.6.4 Post-Thaw Viability Assessment 32
6.7.6.5 Documentation and Record Keeping 32
6.7.6.6 Alarm Systems Surveillance 33
6.7.6.7 Data Recording and Traceability 33
6.7.6.8 Periodic Quality Assessments 33
6.7.6.9 Incorporation of Contamination Management Procedures 33
6.7.7 Storage Capacity and Organization 33
6.7.8 Disposal and Decommissioning 33
6.7.9 Storage and Handling Training 33
6.8 Staining Procedures 33
6.8.1 Standardization of Staining Protocols 33
6.8.2 Selection of Staining Agents 33
6.8.3 Consistency Across Batches 33
6.9 “Passaging” of Organoids 34
6.9.1 Impact on Molecular Characteristics 34
6.9.2 Determination of Passage Limits 34
6.9.3 Documentation and Monitoring 34
6.9.4 Standardization of Passaging Procedures 34
6.10 Molecular Profiling 34
6.10.1 Purpose and Scope 34
6.10.2 Donor and Tissue Characterization 34
6.10.3 Disease Modeling and Personalized Medicine 34
6.10.4 Quality Control and Functional Validation 35
6.10.5 Cryopreservation Impact Assessment 35
6.10.6 Genome Editing Verification 35
6.10.7 Inter- and Intra-Tumor Heterogeneity 35
6.11 Mimicry of Organ Fidelity and Functions 35
6.11.1 Structural and Functional Fidelity 35
6.11.2 Advanced Validation Techniques 36
6.11.3 Fidelity Assessment 36

6.11.4 Documentation and Reporting....36
6.12 Emergency Protocols....36
6.12.1 Equipment Failure Response....36
6.12.2 Power Outage Contingency Plans....36
6.12.3 Emergency Training and Drills....36
6.12.4 Emergency Communication Plan....36
6.12.5 Documentation and Review....37
6.12.6 Risk Mitigation and Preventive Measures....37
6.13 Data Management....37
6.14 Risk Management....37
6.15 Ethical Considerations....37
6.16 Distribution and Access....37
6.16.1 Policy Development....37
6.16.2 Request and Approval Process....37
6.16.3 Transparency and Accountability....38
6.16.4 MTAs....38
6.16.5 Ethical Considerations....38
6.16.6 Transparency Tracking....38
6.16.7 Transport and Shipment of Organoids....38
6.17 Reporting of Organoid Culture Results....38
6.17.1 General Reporting Requirements....38
6.17.2 Examination and Review of Results....38
6.17.3 Notification and Documentation Procedures....39
6.17.4 Special Considerations for Reporting:....39
6.17.5 Automated Reporting Systems....39
6.17.6 Content of Organoid Culture Reports....39
6.17.7 Amendments to Reported Results....39
6.18 Audit and Compliance....39
6.19 Continuous Improvement....39
7 “Quality Assurance” (QA)....40
7.1 Overview....40
7.2 QMS....40
7.3 Quality Policy....40
7.4 Quality Objectives....40
7.5 Quality Planning....40
7.6 Responsibilities and Resources....40
7.7 Process Control....40
7.8 Evidence of Conformity....40
7.8.1 Establishing Measurement Criteria....41
7.8.2 Calibration and Maintenance....41
7.8.3 Data Collection and Analysis....41
7.8.4 Corrective and Preventive Actions....41
7.9 Data Integrity and Security....41
7.10 “Nonconformity” and Corrective Action....41
7.11 Internal Audits....41
7.12 Management Review....41
7.13 Continuous Improvement....41
7.14 Documentation and Record Keeping....41
7.14.1 Documentation Control....42
7.14.2 Record Maintenance....42
7.14.3 Confidentiality and Security....42
7.15 Lifecycle Documentation Tracking and Conditions Management....42
7.15.1 General Requirements....42
7.15.2 “Barcoding Systems” for Organoid Sample Identification....42
7.15.2.1 Essentials....42
7.15.2.2 Specifications....42
7.15.3 Comprehensive Record-Keeping....42
7.15.3.1 Details....42
7.15.3.2 Platforms....43
7.15.4 Standardized Guidelines for Barcoding in OBing....43
7.15.4.1 Guidelines....43
7.15.4.2 Training....43
7.16 Ethical Considerations....43
7.17 Regulatory Compliance....43
Annexes: Standard Operating Procedures (SOPs)....44
List of Abbreviations:....45
Glossary of Terms:....46
Source References:....49

Foreword

In the ever-evolving landscape of biomedical science, the role of “Organoid Biobanking” (OBing) has emerged as a critical component in advancing our understanding of human health and disease. The International Society of Organoid Research (ISoOR) acknowledges the necessity for a standardized approach to this field, which ensures the quality, reliability, and ethical use of organoids in research and clinical applications.

This foreword introduces the ISoOR International Standard for Organoid Biobanking (hereinafter referred to as "ISoOR-ISOB"), a document that encapsulates the collective expertise and best practices of the international organoid research community. Developed through a collaborative and consultative process, this standard aims to provide a comprehensive framework for organizations and stakeholders engaged in OBing.

The standard outlines the essential principles and procedures that govern the establishment, management, and operation of Organoid Biobanks (OBs). It addresses key areas, including “ethical considerations”, donor consent, sample acquisition and processing, storage conditions, “data management”, and the sharing of OB resources.

The development of this standard has been informed by the wealth of knowledge and experience accumulated within the scientific community. It reflects a commitment to excellence and a dedication to advancing the field of organoid research in a responsible and impactful manner.

The ISoOR-ISOB is intended to serve as a guiding document for researchers, institutions, and organizations involved in OBing. It is our hope that the adoption of this standard will lead to a more unified and rigorous approach to organoid research, ultimately contributing to the betterment of human health.

As we move forward, the ISoOR-ISOB will be a living document, subject to periodic review and refinement to ensure its continued relevance and alignment with the latest scientific advancements.

We extend our heartfelt thanks to all those who have contributed to the development of this initiative.

This document employs the following verbal expressions:

— "shall" denotes a mandatory requirement;

— "should" conveys a recommended practice;

— "may" grants permission;

— "can" signifies either a possibility or an ability.

Additionally, terms with specific definitions will be italicized and placed in quotation marks (e.g., “term”) upon their first occurrence, with their definitions available in the glossary on page 46.

1 Scope:

The ISoOR-ISOB provides a framework for the establishment, management, and operation of OBing facilities. The standard covers all aspects of OBing, including ethical considerations, quality management, sample traceability, data security, and technical performance.

The standard is intended for organizations that handle the collection, storage, preservation, and distribution of organoids for various applications, including research, clinical, and therapeutic purposes. The standard is designed to ensure high-quality and competent practices in organoid biobanking on a global scale. Conformity with ISoOR-ISOB demonstrates compliance with the applicable requirements for biobanking activities within the OB's declared operational scope. Such conformity does not, by itself, establish clinical safety or efficacy, demonstrate suitability for administration to patients, or constitute regulatory authorization for the clinical or therapeutic use of organoids. These applications remain subject to applicable legal, regulatory, ethical, and additional technical requirements.

The standard is applicable to OBing facilities, regulatory authorities, accreditation bodies, and stakeholders within the organoid community.

2 Objectives:

2.1 Quality Assurance

To conduct OBing operations under a robust quality management system that adheres to international standards and is tailored to the specific needs of organoid technology.

2.2 Ethical Compliance

To establish guidelines that respect ethical considerations in OBing, emphasizing “informed consent”, confidentiality, and the responsible use of human biological materials.

2.3 Traceability and Provenance

To implement systems ensuring the traceability of organoids from collection to distribution, maintaining accurate records of their history and manipulation.

2.4 Data Integrity and Security

To protect the integrity and security of data associated with organoid samples, in compliance with international data protection regulations.

2.5 Support for Organoid Applications

To support reliable applications of organoids, including drug screening, disease modeling, and personalized medicine, through standardized organoid biobanking practices that ensure documented biological identity, quality, reproducibility, traceability, and suitability for intended use.

2.6 Standardization of Practices

To develop standardized operating procedures for “organoid culture”, preservation, and analysis that reflect the best practices in the field.

2.7 Risk Management

To adopt a proactive approach to risk management, identifying and mitigating risks to organoid quality and integrity.

2.8 Resource Management

To ensure OBing facilities have access to appropriate resources, including trained personnel, suitable facilities, and validated equipment.

2.9 Accessibility and “Equity”

To promote equitable access to OB resources, extending the benefits of organoid technology across various user groups and disciplines.

2.10 Continuous Improvement

To encourage the adoption of new technologies and methodologies that enhance the quality and efficiency of OBing.

2.11 International Collaboration

To support international collaboration in organoid research and OBing by providing a harmonized standard that facilitates global partnerships and data sharing.

3 Basic Criteria

3.1 Overview

The OB shall define and document the scope of its biobanking activities, including the types of organoid material handled, the processes performed, and the services provided. The applicable requirements of ISoOR-ISOB shall be implemented according to this declared scope. Any determination that a requirement is not applicable shall be documented and scientifically or operationally justified, without compromising organoid quality, traceability, ethical compliance, or suitability for intended use.

The OB shall conduct specific risk assessments to address potential risks and opportunities. The overall requirements include:

•The OB should have an appropriate scale and a well-organized, comprehensive organizational structure.

•The OB shall employ competent technical and management personnel appropriate to its activities.

•The OB shall operate with standardized procedures and a robust quality management system.

•The OB shall maintain appropriate procedures for managing and sharing biological sample resources within its declared scope.

•The OB shall demonstrate technical competence for the organoid activities it performs, including research and development where applicable.

•The OB shall maintain or have access to suitable and reliable facilities, equipment, technologies, and services necessary for its declared activities.

The processes involved in establishing and operating the OB should encompass, as applicable, collection, procurement, acquisition, reception, identification, recording, cataloging, classification, inspection, preparation, processing, preservation, cell/tissue culture, storage, data management, disposal, packaging, protection, transportation, and distribution.

3.2 Equity

- The OB shall ensure equity by promoting equal access, fair treatment, and just distribution of benefits and resources for all stakeholders. This includes making the OB's services accessible to all potential users, regardless of background or affiliation, and continuously addressing risks to equity and integrity.
- The OB management shall be committed to maintaining and safeguarding the equity and integrity of the OB. This includes continuously assessing and identifying risks, both internal and external, that may compromise fairness and integrity.
- If any equity risks are identified, the OB shall take prompt measures to mitigate or minimize these risks and document the entire process.

3.3 OB Specimens Management and Ethical Compliance

- The OB shall understand the requirements for biomaterials and related data, ensuring repeatable research outcomes, and adhere to ethical principles.
- The responsibilities of the OB shall be clearly defined and readily available.
- Information related to the activities, processes, and procedures of the OB shall be documented in an understandable format.
- Documentation should include procedures related to the quality management system and relevant information from OB/dedicated area management.
- The OB shall adhere to international and national ethical principles related to biomaterials and associated data.
- The OB shall record the identity of personnel conducting activities.
- The OB shall specify the retention period for record information and related data for each type of biological material after its complete distribution, disposal, or destruction.

3.4 Traceability of Process Information

Ensuring complete and accurate traceability of all process-related information is essential to maintaining the integrity, "reproducibility", and quality of OBs. This subsection outlines the minimum requirements for documenting and tracking the process steps involved in organoid handling, storage, and distribution.

3.4.1 Scope of Traceability

All critical process steps within OBing shall be tracked in a detailed and transparent manner. This includes, but is not limited to:

- Collection of biological materials (e.g., tissue samples, cells).
- Organoid preparation and culture methods.
- Use of reagents, scaffolds, and matrices (with batch numbers and expiry dates).
- "Cryopreservation" procedures and thawing processes.
- Quality control checks and associated results.
- Distribution and shipment of organoids to third-party users.

The traceability system shall allow the reconstruction of the entire process flow for any organoid or batch in the OB.

3.4.2 Documentation and Recording Systems

To support traceability, both paper-based and electronic documentation systems are acceptable, provided they meet the following criteria:

- Unique Identification Codes: Each organoid sample, batch, and associated processes shall be assigned a unique identifier (e.g., barcode or alphanumeric code) that is linked to its complete history.
- Timely Updates: All records shall be updated immediately following any process step to avoid data discrepancies.
- "Audit Trails": Any changes to records, including updates or corrections, shall be traceable with a timestamp, the identity of the person making the change, and the reason for the amendment.

3.4.3 Compliance Verification

The traceability system shall undergo periodic internal audits to ensure accuracy and completeness. Records shall be kept in accordance with regulatory requirements and best practices for data integrity, allowing for easy retrieval and review by authorized personnel or external auditors.

3.4.4 Digital Systems for Process Traceability

Where digital or automated systems are used for OBing processes, they shall be qualified or validated, as appropriate for their intended use, in accordance with 5.3.6.5, to demonstrate reliability and compliance with applicable data security requirements. The digital system shall:

- Allow secure access only to authorized personnel.
- Provide robust backup and recovery mechanisms.
- Ensure all process-related data are stored in a way that preserves their integrity over time (e.g., protection against data loss or corruption).

3.4.5 Traceability in Collaborative Projects

When OBing activities involve collaborations between multiple institutions or international parties, it is imperative that the traceability systems employed by all involved parties are interoperable. A standardized framework for data sharing, material transfer, and process recording shall be established at the outset of the project to ensure traceability is maintained across institutions. This shall include the implementation of a "Material Transfer Agreement" (MTA) governing the exchange of organoid materials, which specifies traceability requirements and the responsibilities of each party.

3.4.6 Incident Management and Non-Compliance Reporting

If any deviation from the standard process occurs, the event shall be documented, including the nature of the incident, the corrective actions taken, and any potential impact on organoid quality or consistency. Non-compliance with traceability requirements shall be addressed promptly, and documented actions shall be taken to prevent recurrence.

3.5 Legal and Ethical Requirements

3.5.1 "Legal Ownership" of Organoids and Data

- The legal ownership of organoids and associated data may vary based on local, national, or international laws. OBs shall clarify ownership through formal agreements and ensure that the terms of ownership are clearly defined for both biological samples (organoids) and any derived data.
- Ownership agreements shall be reviewed periodically to remain compliant with evolving legal frameworks.

3.5.2 "Data Protection and Privacy"

- OBs shall implement appropriate safeguards to protect the privacy and confidentiality of personal and sensitive data associated with organoid samples, in accordance with data protection laws.
- Any identifiable data linked to organoid samples shall be processed and stored in a manner that complies with applicable data privacy laws and the principles of confidentiality, integrity, and availability.

3.5.3 "Access to Organoids and Data"

- OBs shall clearly define and document "access agreements" that specify who can access organoid samples and related data, under what conditions, and for what purposes.
- Access agreements should be in place to ensure that any sharing of organoid materials complies with the informed consent process and ethical standards.
- A MTA shall be established prior to any transfer of organoid materials to external parties. The MTA shall outline the terms of access, traceability requirements, and the obligations of the receiving party regarding the use, storage, and further distribution of the materials.

3.6 Compliance with "Intellectual Property (IP) Rights"

3.6.1 Intellectual Property Considerations

- OBs shall clarify the ownership and rights to any IP generated from research using organoid samples.
- Agreements should outline the terms of IP ownership, whether it is held by the OB, the researcher, or external stakeholders.
- OBs shall respect and adhere to intellectual property laws when commercializing organoid-based research or products.

3.7 Legislative and Policy Awareness

3.7.1 Monitoring and Implementation of Legislative Changes

- OBs shall have mechanisms in place to regularly monitor changes in legislation and research policies that may impact the collection, storage, or use of organoid samples.
- It is the responsibility of the OB to adapt its procedures and practices in response to new legislative or regulatory developments, ensuring continued compliance with all applicable laws.

4 Structural Requisites

4.1 Organizational Structure

The organizational structure of the OB should be designed to clearly define roles, responsibilities, and lines of authority among management, scientific, and technical staff. The roles and responsibilities shall be documented, with clear accountability and oversight supporting the ethical and legal use of biological materials.

The OB shall identify, assess, document, and manage potential conflicts of interest and other risks to impartiality arising from organizational, financial, commercial, professional, or personal relationships. Appropriate measures shall be implemented to prevent such risks from compromising scientific evaluations, quality decisions, access to resources, or other biobanking activities. The effectiveness of these measures shall be periodically reviewed.

4.2 Facilities and Infrastructure

The OB shall provide facilities appropriate to the activities within its declared operational scope, including culture, processing, storage, and administrative functions, as applicable. The infrastructure should meet the statutory and regulatory requirements of the operating jurisdiction, ensuring that it supports both quality and risk management objectives. OBs should be equipped with appropriate safety features and designed to maintain environmental conditions that preserve the integrity of organoids. The facility's layout shall support the workflow and minimize cross-contamination risks, reflecting the guidelines for best practices in OBing.

4.3 Equipment and Materials

The OB shall possess or have controlled access to the instruments, equipment, and materials necessary for the activities within its declared operational scope, including organoid culture, cryopreservation, and analysis, as applicable. Equipment shall be qualified, verified, calibrated where applicable, and maintained in accordance with Section 5.3 to ensure accuracy and reliability. The selection and procurement of materials should be based on documented protocols to ensure consistency and quality in the OBing process, reflecting the requirements for quality control and the handling of biological specimens.

4.4 Information Management System

An effective Information Management System (IMS) is vital for the comprehensive management of records, tracking samples, and ensuring the traceability of organoids throughout the OBing process. The IMS should be architected to uphold data integrity, security, and confidentiality, in alignment with relevant regulatory frameworks for data protection and OBing standards. Key features should include robust backup and recovery solutions to ensure that records are securely stored and easily retrievable. Additionally, the IMS shall facilitate compliance with legal and ethical standards, providing comprehensive audit trails and documentation control to support operational transparency.

4.5 “Quality Management System” (QMS)

The OB shall implement a comprehensive QMS that establishes the structural requisites necessary for effective quality oversight. This includes a quality policy, quality objectives, and defined management responsibilities. The QMS should encompass all operational aspects of OBing, from procurement to distribution, and outline processes for continuous improvement and internal audits. This framework ensures that all operations are conducted under controlled conditions, with ongoing monitoring to maintain high standards of quality and consistency.

4.6 Personnel Competence

All personnel involved in OBing shall have the necessary education, training, skills, and experience to perform their tasks competently. The OB should implement a training program that ensures all staff are regularly assessed and receive ongoing education to stay current with advancements in the field. Competence should be maintained through continuous professional development, and training records shall be meticulously maintained.

4.7 Safety and Environmental Conditions

The OB shall maintain a safe working environment and establish environmental conditions that ensure the integrity and stability of organoids during culture, storage, and processing. Safety protocols should include biohazard containment, emergency response plans, and regular safety audits. Environmental monitoring systems should be implemented to continually assess and maintain optimal conditions, with provisions for immediate corrective actions if needed.

4.8 Ethical Considerations

Ethical guidelines shall be established and followed, addressing informed consent, confidentiality, donor rights, and the responsible use of organoids and associated data. The OB shall verify and document the applicable ethical authorization, consent conditions, or other legally and ethically valid basis for obtaining, processing, storing, using, and distributing human-derived biological materials and associated data.

The OB shall establish documented procedures for managing consent restrictions, changes in permitted use, and withdrawal of consent, where applicable. These procedures shall define the assessment and implementation of restrictions on future use, storage, or distribution, including appropriate actions concerning previously shared materials or data. Any legal, technical, or practical limitations on withdrawal shall be documented and addressed in accordance with applicable requirements. Cross-border transfers shall comply with relevant ethical, legal, regulatory, and contractual obligations.

4.9 “Regulatory Compliance”

The OB shall ensure full compliance with all relevant international, national, and regional regulations governing research, biobanking, and the use of human biological materials. This includes adhering to specific legal requirements within the jurisdiction, as well as any applicable international agreements or guidelines. Regulatory compliance should be integrated into all aspects of the OB's operations, with regular reviews and updates to reflect changes in the legal and regulatory landscape.

4.10 External Services and Supply Chain

The OB shall establish robust procedures for the evaluation, selection, monitoring, and re-evaluation of external suppliers and service providers. These procedures should ensure that all external resources, including supplies and services, meet the required standards for quality and suitability in OBing operations. The supply chain should be managed to minimize risks and ensure the consistent quality of inputs, reflecting best practices in supply chain management and quality control.

5 Resource Criteria

5.1 Overview

The OB shall ensure the availability of personnel, facilities, equipment, materials, information systems, and financial resources appropriate to its declared operational scope and necessary to maintain the quality, safety, and continuity of its biobanking activities.

The OB shall establish and maintain documented resource planning procedures to assess its operational needs, identify potential resource limitations, and implement appropriate measures to mitigate risks to organoid quality, traceability, storage integrity, and continuity of operations.

Financial and operational arrangements shall be sufficient to support the OB's activities and obligations, including the maintenance, preservation, transfer, or appropriate disposition of biological materials in the event of significant resource constraints or discontinuation of operations.

5.2 Human Resources

- Personnel shall adhere to established norms and processes, with regular competency assessments and training. The OB should provide detailed job descriptions, clearly defining roles and responsibilities according to its standards. Regular reviews of personnel abilities and qualifications should be conducted, with comprehensive records maintained, including names, signatures, identification codes, and employment dates.
- The health and safety of all personnel shall be ensured through adherence to safety regulations and protocols, with comprehensive records of all processes maintained to prevent workplace hazards. This includes conducting risk assessments for all biological and chemical materials, processes, and equipment, and providing the necessary safety training to mitigate potential risks.
- All personnel, including internal staff and external collaborators, shall maintain impartiality and confidentiality, particularly regarding access to biological database data.

5.2.1 Competence and Skill Evaluation

- All personnel shall pass competency assessments before independently performing designated activities. If a staff member's abilities do not meet the required standards, corrective measures should be taken, including professional skills training when necessary.
- The OB should conduct regular competency assessments of relevant personnel annually, based on task requirements and the unique characteristics of different positions. This ensures continuous improvement and adaptation to evolving standards.
- For personnel involved in high-complexity testing, competency reviews should be conducted more frequently during their first year of work. Their capabilities should be evaluated whenever new processes and requirements are introduced.
- Personnel competency assessment files shall be meticulously recorded and maintained as evidence of professional abilities and education/training. These records serve as proof of the OB’s commitment to maintaining high standards.

5.2.2 Training

The OB shall establish, implement, and maintain policies, processes, and procedures to ensure that personnel are trained, competent, and comply with quality, safety, and ethical standards. The training program shall cover the following:

5.2.2.1 Preliminary job training

The OB shall provide induction training to all new personnel. This shall introduce OB policies, protocols, and laboratory procedures, emphasizing good practices in laboratories.

5.2.2.2 Quality system training

The OB shall conduct training on QMS to maintain and continuously improve performance across all OBing activities.

5.2.2.3 Job-specific training

The OB shall ensure personnel receive training specific to their assigned tasks, including updates as responsibilities evolve.

5.2.2.4 Continuing education

The OB should facilitate continuing education programs to ensure personnel, particularly technicians performing key tasks, maintain competence and meet OB certification requirements.

5.2.2.5 "Good Laboratory Practice" (GLP) training

The OB shall train personnel in GLP principles, including aseptic techniques, equipment handling, laboratory hygiene, and waste management.

5.2.2.6 Biosafety training

The OB shall ensure personnel receive biosafety training appropriate to the risk level of OB operations, covering biological material handling and emergency procedures.

5.2.2.7 Traceability procedures training

The OB shall train personnel in traceability requirements, emphasizing accurate record-keeping, sample labeling, and chain-of-custody maintenance throughout the organoid lifecycle.

5.2.2.8 Ethical and legal compliance training

The OB shall ensure that personnel are trained in ethical requirements, including informed consent, data protection, and MTAs.

5.2.2.9 "Standard Operating Procedures" (SOPs) training

The OB shall ensure that personnel are trained to follow relevant SOPs for organoid collection, culture, storage, transportation, and data management.

The OB shall maintain records of all training provided and assess personnel competency at regular intervals to confirm compliance with applicable standards and procedures.

5.3 Equipment

5.3.1 Acquisition and Installation Process

The OB shall establish policies for equipment acquisition, operation, maintenance, calibration, and traceability. Equipment specifications and selection criteria should be defined before purchase. All critical equipment shall be qualified for its intended use, with repairs and upgrades evaluated and requalified as appropriate.

- Equipment shall be installed according to the manufacturer's specifications to ensure proper functioning and compliance with industry standards.

5.3.2 Verification and Operation of Technical Resources

- The functionality of equipment shall be verified before use against applicable manufacturer specifications and requirements for its intended use. Information and data management systems and their components shall be qualified or validated, as appropriate for their intended use, in accordance with 5.3.6.5. AI systems shall additionally meet the validation requirements of 5.3.7.4.
- The OB shall demonstrate that equipment performs as expected for its intended use, meeting or exceeding the manufacturer's specifications. This includes regular testing and validation.
- Equipment shall be used in accordance with the manufacturer's written instructions, with processes for scheduled monitoring and maintenance in place to ensure continued compliance and performance.

5.3.3 Calibration and Accuracy of Tools and Devices

- The OB shall identify equipment that requires maintenance in a calibrated state. Measurements and accuracy requirements shall be determined, with a detailed calibration process defined, including equipment type, unique identification, location, frequency of checks, check method, acceptance criteria, and limitations.

- Equipment used for inspection, measuring, and testing shall be calibrated before initial use, after repair, and at prescribed intervals. Equipment shall be safeguarded from adjustments that may invalidate calibration settings, ensuring accurate and reliable results.

5.3.4 Equipment Inspection, Maintenance, and Servicing

- A defined process shall be in place for handling equipment found to be out of calibration or specification. This includes assessing the validity of previous inspection and test results and determining the conformance of provided OB services to required specifications.
- Cleaning and sanitization methods and intervals shall be defined for each piece of equipment. Suitable environmental conditions shall be ensured for calibrations, inspections, measurements, and tests.
- Equipment shall be monitored to ensure defined parameters are maintained, with maintenance and repairs performed by qualified individuals according to the manufacturer's instructions.

5.3.5 Monitoring of Equipment

The OB shall maintain records of equipment use to ensure unique identification and traceability. This includes linking specific equipment to all associated OB activities, ensuring comprehensive documentation and accountability.

5.3.6 Data Management and Information Management Systems

5.3.6.1 General

- The OB shall establish, document, implement and maintain one or more information and data management systems appropriate to the nature, scale, sensitivity and intended use of the biological material and associated data.
- The implementation of these requirements may be integrated into existing organizational processes and responsibilities, provided that their effectiveness can be demonstrated and documented.
- The systems shall support data quality, integrity, traceability, metadata completeness, interoperability, controlled access and sharing, privacy, security and availability throughout the data lifecycle. Requirements for data integrity and security, documentation and record keeping, and lifecycle traceability specified in 7.9, 7.14 and 7.15 shall apply.

5.3.6.2 Governance and risk management

- The OB shall define accountability, authority and competence for the governance, operation, review and improvement of its information and data management systems. Documented policies and procedures shall be maintained to identify, assess, control and review risks to data and associated biological material.
- Controls shall be proportionate to risk and shall address, as applicable, loss, corruption, unauthorized access or alteration, inappropriate use or sharing, data leakage, breach of privacy, loss of traceability and unavailability of critical information. Residual risks and exceptions shall be reviewed and accepted by authorized personnel.

5.3.6.3 Data quality, metadata and provenance

- The OB shall define and maintain data and metadata sufficient to identify biological material and associated data, interpret their meaning, assess fitness for intended purpose, and support traceability and reproducibility. Links among source material, organoids and derivatives, processing history, quality-control results and associated datasets shall be maintained throughout their lifecycle. For organoid-related biological material, metadata shall include, as applicable to the intended use, relevant biological and culture variables such as organoid type and source, culture conditions, dissociation method, passage number, extracellular-matrix material and lot, and other variables that may materially affect organoid characteristics, quality or reproducibility.
- The OB shall establish appropriate controls to preserve the completeness, accuracy, consistency, traceability, accessibility for authorized users, and availability of critical data. Critical data shall be identified and documented based on the potential impact of their loss, inaccuracy, alteration or unavailability on organoid quality, traceability, donor rights or suitability for intended use. Their integrity shall be verified at defined stages and following events that could affect their integrity.
- Data quality requirements and acceptance criteria shall be defined for critical data. Data that do not meet specified requirements shall be identified and controlled to prevent unintended use or distribution. Such controls may include documented correction, restriction of access or use, or other authorized measures, as

appropriate. The creation, revision, correction, transfer, import, export, migration and deletion of critical data shall be controlled and traceable. Changes and corrections shall not obscure the original record. Records of changes shall identify the person or system making the change, the date and time of the change, and the reason for any amendment or correction.

- Acceptance criteria shall distinguish data-quality deficiencies from expected biological heterogeneity or phenotypic variation. Organoids or associated data that differ from reference morphological or phenotypic characteristics shall not be excluded solely on that basis unless predefined and scientifically justified quality criteria indicate that they are unsuitable for the intended use.
- Data sets used for AI development, validation, testing, evaluation or operation shall be identified and controlled to prevent inappropriate overlap or transfer of information that could compromise the validity of performance assessments, and to preserve provenance and applicable use restrictions. AI outputs that inform quality, access, distribution, safety, research or reporting decisions shall be managed as critical data where applicable and shall remain traceable to the applicable data, AI system and version.

5.3.6.4 Interoperability, access and sharing

- The OB shall use documented data structures, identifiers, terminology and exchange arrangements that preserve the meaning, quality, provenance and applicable restrictions of data. Recognized community practices shall be used where suitable to support interoperability and long-term accessibility.
- Human-related data shall be classified according to sensitivity and identifiability. Data shall be considered potentially identifiable where their combination with other reasonably available information could permit re-identification. Pseudonymized or de-identified data shall be protected according to documented residual re-identification risk and shall not be treated as non-sensitive solely because direct identifiers have been removed.
- Before human-related data are made available for use or sharing, the OB shall determine and document the controls necessary for the authorized purpose, including, as applicable, data minimization, pseudonymization, de-identification, aggregation, access restriction and conditions for re-identification. Re-identification keys or equivalent linking information shall be separately protected and accessible only to authorized personnel.
- Access to and sharing of data shall be authorized and controlled in accordance with applicable consent, ethical, legal, privacy and contractual requirements. Access to human-related data shall be limited to the minimum data necessary for an authorized purpose, granted to authorized personnel and periodically reviewed at intervals determined by the OB based on the sensitivity of the data, associated risks, applicable legal and regulatory requirements, and the nature of the authorized use. The OB shall retain sufficient records of access, disclosure, transfer and distribution and shall provide recipients with applicable restrictions, responsibilities and subsequent material changes affecting permitted use.
- Where data are shared with external organizations, the OB shall establish documented data-sharing arrangements defining the permitted purposes and uses, the responsibilities of the providing and receiving parties, applicable safeguards, and conditions for further sharing, retention and disposal, as appropriate to the nature and sensitivity of the data and applicable requirements.

5.3.6.5 System control, continuity and lifecycle management

- Information and data management systems and their components, including hardware, software, databases and supporting infrastructure, shall be qualified or validated as appropriate for their intended use before implementation. Documented configuration and version information, including authorization for modifications, shall be maintained. Internally developed software shall be subject to documented lifecycle requirements appropriate to its intended use.
- Information and data management systems shall remain controlled throughout operation, modification, migration and retirement. Changes that may affect data quality, integrity, traceability, availability, privacy or security shall be authorized, assessed and documented. The impact of such changes on previously recorded, processed or shared data shall be assessed where applicable.
- The OB shall establish documented arrangements for backup, recovery, retention, archiving and authorized disposal. Backup and recovery arrangements shall protect the confidentiality and integrity of data. The ability to restore essential data and perform critical activities shall be verified at planned intervals.
- The OB shall maintain documented and verified contingency arrangements to ensure the continuity of critical activities and access to essential data in the event of electronic-data unavailability. These arrangements may

include alternative electronic systems or controlled manual procedures, as appropriate to the nature and risks of the activities. Their readiness and reliability shall be verified at planned intervals, including the accessibility, currency, integrity and security of essential data. Records generated through manual contingency procedures shall remain traceable and shall comply with the applicable documentation and record-keeping requirements of this standard.

- The effectiveness of the systems and controls shall be monitored and periodically reviewed, and identified failures or nonconformities shall be addressed through corrective action and continual improvement.

5.3.7 Appropriate and Responsible Use of Artificial Intelligence Systems

5.3.7.1 General

- The OB shall use an AI system only for a defined, justified and approved purpose. The extent of governance, evaluation and oversight shall be proportionate to the intended use, operational context and potential impact of the system.
- AI development and use relying on data controlled under 5.3.6 shall meet the requirements specified in that section. The requirements for traceability in 3.4 and for legal and ethical handling of organoids and associated data in 3.5 shall apply to AI-assisted activities.
- This section shall apply to AI systems developed by the OB, acquired from or operated by third parties, embedded in other systems, or otherwise used in OB activities. The OB shall ensure that the use of AI complies with applicable legal, regulatory, ethical, consent, privacy, security and contractual requirements.

5.3.7.2 Governance and accountability

- The OB shall establish accountability structures for the governance of AI risks. Policies, processes, procedures and practices shall be in place to support the mapping, measurement and management of such risks throughout the AI system lifecycle.
- The OB shall maintain an up-to-date inventory of AI systems used in OB activities. The inventory shall identify, as applicable, the system, version or provider, intended purpose, accountable owner, authorized users, risk classification and current authorization status. Where relevant information about a third-party AI system is unavailable, the OB shall document the information gaps, assess their impact on validation, traceability and risk, and implement appropriate controls before authorizing use.
- Each AI system shall have a defined accountable owner, authorized users and appropriate human oversight. Responsibilities for approval, operation, evaluation, monitoring, change and incident response shall be assigned to competent personnel. Third-party systems and services shall remain subject to the OB's governance and risk-management requirements.
- AI governance shall be integrated into the IMS and QMS established under 4.4, 4.5 and 7.2. AI inventories, approvals, risk assessments, validation evidence, monitoring records, change records and incident records shall be controlled as documented information in accordance with 6.3 and 7.14. Relevant AI governance activities and results shall be included in internal audits and management review under 7.11 and 7.12.
- At planned intervals, the OB shall review emerging AI technologies, cybersecurity threats, scientific evidence, applicable standards and regulation, and material provider changes, and shall document whether its controls remain adequate.

5.3.7.3 Risk assessment and authorization

- Before development, acquisition or use, the OB shall document the intended purpose, users, operating context, expected benefit, relevant limitations and reasonably foreseeable misuse or failure of the AI system. The documented context shall include the categories, sensitivity and identifiability of data used by the system and the applicable consent, use and sharing restrictions. Risks shall be assessed against defined acceptance criteria, and a documented decision shall determine whether development, deployment or continued use may proceed. The rationale for determining risk classification, acceptance criteria and the adequacy of selected controls shall be documented and available for review.
- The assessment shall consider, as applicable, scientific validity, reliability, safety, security, data leakage, breach of privacy or re-identification, harmful bias or discrimination, legal and ethical obligations, human consequences and operational continuity. AI shall not be used outside its approved purpose or conditions unless the change has been assessed and authorized.

- Identifiable, potentially identifiable or sensitive data shall not be submitted to an external AI system or service unless the OB has documented authorization and an assessment demonstrating that the intended processing complies with applicable consent, legal, privacy, security and contractual requirements. The assessment shall define the data categories, permitted processing, provider responsibilities, access restrictions and safeguards applicable to the use.
- Where an AI system or service is provided, hosted, operated or supported by an external party, the evaluation, selection, monitoring and re-evaluation requirements of 4.10 and 5.5 shall apply.

5.3.7.4 Validation, monitoring and lifecycle control

- An AI system shall be evaluated before use to demonstrate its suitability for its approved intended purpose. Verification and validation shall be performed according to the system's risk classification and potential impact on organoid quality, characterization, traceability, donor rights, data security, access, distribution, or reporting.
- Where AI systems are used to evaluate organoids or associated biological data, validation shall consider, as applicable, the variability of organoid types, biological sources, culture conditions, passage numbers and other relevant factors that may affect system performance. Validation shall adequately represent the conditions and relevant biological variability within the approved intended use. Limitations and conditions not covered by validation shall be documented and addressed through appropriate risk controls.
- For AI systems whose outputs may materially affect organoid biobanking activities, associated biological data, donor rights, or consequential decisions, the OB shall define appropriate performance and risk measures, monitoring methods, review intervals, and action thresholds according to their intended purpose and risk classification. Monitoring methods and frequencies shall reflect the frequency of use, availability of reference outcomes, potential consequences of performance deterioration and associated risks. Performance and risk shall be monitored during use. Monitoring shall include changes in data characteristics, quality, completeness, distribution, source population, operating context or output patterns that could indicate data drift or deterioration in model performance. Where AI performance may be influenced by biological variability, monitoring shall also consider relevant changes in the biological characteristics of organoid cultures, including passage-associated changes, differentiation state, contamination status, culture conditions, and batch-dependent effects of extracellular-matrix or other critical culture materials. Where suitable reference outcomes are available, performance shall be assessed against the approved acceptance criteria. Where suitable reference outcomes are unavailable or delayed, the OB shall establish alternative risk-based monitoring arrangements, which may include surrogate performance indicators, periodic expert review, enhanced human oversight or restrictions on AI-assisted activities, as appropriate to the intended use and associated risks. The limitations of such monitoring arrangements shall be considered when determining whether continued use of the AI system remains acceptable.
- An exceedance of an action threshold or other material deterioration in performance or risk shall be investigated and shall result in appropriate corrective action, including restriction, suspension, revalidation, update or retirement of the AI system. Investigations of AI performance deterioration shall consider relevant data-related, biological, technical and operational factors when determining appropriate corrective actions. Material changes in the system, data, operating context, provider or intended purpose shall be assessed and shall trigger revalidation before continued use where the previous validation evidence no longer applies. Any update intended to address data drift or performance deterioration shall be assessed, authorized and validated before use. Material failures, deteriorations or nonconformities shall be managed in accordance with 7.10.
- The OB shall maintain a documented process for reporting, investigating and managing AI incidents and near misses, including unsafe outputs, privacy leakage, harmful bias and security compromise. The process shall provide for containment, corrective action, recovery or reversion, controlled suspension or retirement, and documented lessons learned.
- Records necessary to reconstruct an AI-assisted activity, including the relevant data, AI system and version, validation status, output and relevant change history, shall be maintained in accordance with 3.4, 7.9, 7.14 and 7.15. For consequential activities involving adaptive or generative AI, records shall include, as applicable, the inputs, instructions, configuration, retrieved sources, output and model version. Where required information cannot be obtained from an external AI provider, the OB shall document the limitation, assess its impact on traceability and accountability, and determine whether the available evidence and additional controls are sufficient for the intended use.

5.3.7.5 Human oversight, transparency and guardrails

- The role and authority of human decision-makers shall be defined. Relevant personnel shall be able to recognize limitations, review and challenge outputs, intervene or override the system, and escalate cases that are uncertain, anomalous or outside the approved scope.
- Controls shall prevent unauthorized or inappropriate AI use and shall reduce the risk of unreliable output, data leakage, breach of privacy, re-identification, harmful bias and discrimination. Decisions arising from consequential AI-assisted activities shall not be fully automated unless such automation has been specifically justified, validated and authorized. Documentation shall be sufficient to support accountability, traceability, review and corrective action while protecting confidential and personal information.
- Where AI supports access, distribution, result selection, review, release or reporting, the applicable requirements of 6.16 and 6.17 shall be met. AI-assisted outputs shall not replace authorization by competent personnel where such authorization is required by this standard or applicable legal and regulatory requirements.

5.3.7.6 Competence and awareness

- Personnel who develop, acquire, operate, oversee, evaluate or approve AI systems shall be trained and competent for their assigned responsibilities. For AI systems used to evaluate organoids or organoid-associated biological data, the personnel responsible for development, validation and evaluation shall collectively possess, or have documented access to, appropriate competence in organoid biology, culture processes, relevant quality attributes and sources of biological variability. Training and awareness activities shall address, as applicable, data protection, authorized data use, system limitations, performance monitoring, data drift, model performance deterioration, human review, override, escalation and incident reporting.
- The OB shall maintain records of relevant training and competence assessment and shall review competence when the assigned role, AI system, operating context or applicable requirements change. The competence and training record requirements of 4.6, 5.2 and 6.4 shall apply to personnel assigned AI-related responsibilities.

5.4 Infrastructure and Ambient Parameters

Infrastructure and the ambient conditions required for the execution of OBing activities shall be identified, controlled, and maintained to meet specified quality control standards. This includes preventing cross-contamination and ensuring suitable conditions for organoid storage.

- Procedures shall ensure that biological materials and related data are aligned with their intended use, biosafety, and biosecurity standards.
- Facilities housing incompatible activities shall be effectively isolated from each other to prevent cross-contamination.
- Environmental conditions shall be suitable for organoid storage, ensuring they do not adversely impact the suitability for intended use.
- Environmental conditions shall be measured, monitored, controlled, and recorded as required to maintain the quality of biological materials and related data, and to ensure the health and safety of personnel.

5.5 Third-Party Operations

- The OB shall evaluate and monitor external suppliers to ensure they meet OB requirements. Documented information and necessary actions from evaluations shall be retained, and external processes shall be communicated to providers, recipients, and users.
- Performance evaluation, selection, monitoring, and re-evaluation standards for external suppliers shall be determined based on their ability to meet the OB's requirements.
- The owner of intellectual property rights arising from the collaboration with external suppliers should be clearly defined in advance.

5.6 Laboratory Supplies, Chemicals, and other Consumables

5.6.1 Overview

The OB shall manage the selection, procurement, storage, and use of reagents and consumables to ensure quality and consistency. These protocols are essential for maintaining the integrity and reliability of biological samples and experimental results.

5.6.2 Receipt and Storage

Upon receipt, all reagents and consumables shall be inspected for damage, correct labeling, and compliance with order specifications. Storage conditions should be defined and strictly adhered to, including temperature, humidity, and light exposure requirements, as specified by the manufacturer. Appropriate storage logs shall be maintained.

5.6.3 Acceptance Testing

New batches of critical reagents and consumables should undergo acceptance testing to verify their performance and suitability for intended use. This testing shall be documented and include criteria for acceptance or rejection. Records of these tests shall be maintained and reviewed periodically.

5.6.4 Inventory Management

An inventory management system should be in place to track the availability and usage of all reagents and consumables. This system shall include details such as batch numbers, expiration dates, storage locations, and quantities. Regular audits of inventory should be conducted to ensure no expired or low-quality items are used in the OB.

5.6.5 Instructions for Use

All personnel shall have access to and follow detailed instructions for the proper use of reagents and consumables. These instructions should be based on manufacturer recommendations and validated internal protocols to ensure consistency and accuracy in experimental procedures.

5.6.6 Adverse Incident Reporting

A system for reporting, investigating, and resolving adverse incidents involving reagents and consumables shall be established. This system should include a process for identifying the root cause of the issue, implementing corrective actions, and preventing recurrence. Records of all adverse incidents and resolutions shall be maintained.

5.6.7 Records

Detailed records of all reagents and consumables shall be kept, including purchase orders, certificates of analysis, receipt dates, storage conditions, and usage logs. These records ensure traceability, facilitating quality control and regulatory compliance.

5.6.8 Standardization of Reagents for Organoid Development, Transportation and Storage

5.6.8.1 General Requirements for Reagents

The reagents used throughout the lifecycle of organoids, including development, culture, storage, and transportation, shall be standardized and controlled to ensure consistency, reliability, and suitability for their intended function and the requirements of the organoid model. Reagent selection and formulation shall consider relevant biochemical, nutritional, and environmental requirements, as applicable to the process and intended use. This includes, but is not limited to, reagents for culture media, cryopreservation, and extracellular matrix (ECM) preparation.

5.6.8.2 Biochemical Composition and Optimization

Reagents used for organoid development, culture, storage, and transportation shall be selected and, where appropriate, optimized according to their intended function and the biological requirements of the organoid model. Nutrient concentrations, growth factors, and other critical additives shall be appropriate to the model's characteristics and intended use. Components that do not replicate physiological conditions may be used where scientifically justified for organoid culture, differentiation, preservation, or other biobanking processes, provided their suitability and potential effects on organoid quality are evaluated and documented.

5.6.8.3 Heterogeneity and Functional Support

Reagents used for organoid development and culture shall support the biological characteristics, cellular composition, and functional properties relevant to the organoid model and its intended use. Where preservation of cellular heterogeneity, tissue organization, or specific physiological functions is required, appropriate signaling molecules, ECM components, and other critical factors shall be selected and controlled to support these characteristics.

The suitability of critical reagents and their potential effects on relevant organoid quality attributes shall be evaluated and documented according to scientifically justified criteria.

5.6.9 "Biochemical Consistency"

Consistency in biochemical composition shall be maintained across all batches of reagents and materials used in organoid generation, culture, storage, and transportation. This includes ECM materials, culture media, supplements, additives, cryoprotectants, and other critical reagents. Uniformity in these components is essential for ensuring reproducibility, reliability, and quality in organoid-based research and applications.

Any changes in formulation, material sourcing, or manufacturing processes for these reagents shall be thoroughly documented, validated, and communicated to end-users. Validation processes shall confirm that such changes do not negatively affect organoid quality, consistency, or performance.

Batch-to-batch consistency for all reagents shall be monitored through robust quality control measures. Deviations from established standards shall trigger corrective actions to maintain the integrity of the OBing process and research outcomes.

5.6.10 ECMs

ECMs, in the context of organoid culture, refer to the supportive scaffolding materials either natural or synthetic that provide structural and biochemical support for the growth, maintenance, and functionality of organoids.

5.6.10.1 Material Selection

Biocompatible materials that closely mimic the native components of the ECM should be selected to effectively support organoid growth, development, and function.

5.6.10.2 Composition and Batch Consistency

For organoids developed in ECM mimetics, such as scaffolds and hydrogels, consistency is essential to ensure reproducibility and standardization within OBing. The formulation of these materials shall be clearly defined and controlled to support reliable outcomes in research and other applications.

5.6.10.2.1 Avoidance of Undefined Matrices

The use of undefined matrices, such as those derived from animal sources that may introduce variability, shall be minimized. Preference shall be given to chemically defined or synthetic matrices, where the composition is tightly controlled.

5.6.10.2.2 Use of Animal-Derived Products

In some instances, animal-derived materials may be the only viable option for certain organoid models. In these cases, variability inherent in these materials shall be carefully managed.

5.6.10.2.3 Quality Control and Mitigation of Variability

Where animal-derived products are used, stringent quality control measures shall ensure consistency between batches. These measures include:

- Comprehensive batch testing to verify and document biochemical consistency.
- Establishing minimum purity and composition standards.
- Ongoing performance evaluations, such as organoid growth rates, differentiation potential, and functional properties.

If significant variability is detected, alternative materials or refined quality control protocols shall be implemented to mitigate risks.

5.6.10.2.4 Balancing Quality and Reproducibility

When reproducibility is paramount, chemically defined or synthetic alternatives shall be prioritized. However, the controlled use of animal-derived products is acceptable, provided the potential for variability is minimized through rigorous quality control protocols.

5.6.10.3 "Biocompatibility"

ECMs shall be evaluated for biocompatibility using scientifically justified methods appropriate to their origin, composition, intended application, and the characteristics of the organoid model. The evaluation shall address relevant potential adverse effects, including cytotoxicity and effects on organoid viability, growth, differentiation, and functionality. Immunogenicity shall be assessed where relevant to the intended application and associated risks. Assessment methods, acceptance criteria, and results shall be documented.

5.6.10.4 Mechanical and Physical Properties

The mechanical and physical properties of ECM materials, including stiffness, elasticity, strength, and porosity, shall be considered according to their relevance to the organoid model and intended use. Critical properties shall be defined, evaluated, and controlled using scientifically justified criteria to ensure suitability for organoid development, maintenance, and functional performance, as applicable.

5.6.10.5 Decellularized Tissue ECM

Hydrogels derived from decellularized tissues shall be processed in a manner that preserves essential biochemical signals for organoid growth, while maintaining batch-to-batch consistency to ensure reliable performance.

5.6.10.6 Stiffness and Elasticity of ECMs

Where stiffness and elasticity are relevant to organoid quality or performance, the OB shall establish appropriate methods and acceptance criteria for evaluating and controlling these properties. Batch-to-batch variability and potential effects on organoid characteristics shall be assessed according to scientifically justified criteria. Defined or tunable hydrogel systems may be used where appropriate but shall not be universally required.

5.6.10.7 Mechanical Pressure Exerted by ECMs

Where relevant, the OB shall evaluate the potential effects of ECM-associated mechanical forces, including confinement, stiffness, and mechanical stress, on organoid morphology, growth, differentiation, and functional characteristics.

Critical mechanical conditions and their acceptable variability shall be defined and controlled according to the organoid model, culture system, and intended use. Deviations that may compromise organoid quality or reproducibility shall be documented and appropriately addressed.

5.6.10.8 Reference-Stock ECMs for Functional Testing

The OB shall establish scientifically justified procedures to evaluate the consistency and suitability of ECMs used in organoid culture and functional testing.

Where appropriate, reference-stock ECMs or qualified reference lots shall be maintained to assess batch-to-batch variability and its potential effects on organoid growth, morphology, and functional characteristics. Alternative methods of demonstrating ECM comparability may be employed where scientifically justified.

ECM identification, batch information, storage conditions, evaluation methods, acceptance criteria, and results shall be documented to ensure traceability and reproducibility.

5.6.10.9 Risk Assessment

A thorough risk assessment should be conducted for all ECMs to identify potential hazards. Appropriate risk management strategies shall be implemented to mitigate any identified risks.

6 Operational Criteria

6.1 Overview

These criteria apply to all stages of OBing, from the procurement of biological samples to the storage, processing, and distribution of organoids.

6.2 Quality Management

A comprehensive QMS shall be implemented to govern all operational aspects of the OB, ensuring consistency, traceability, and continuous improvement.

6.3 “Documentation and Record Keeping”

All procedures, processes, and transactions shall be thoroughly documented, with records maintained in a secure, accessible, and organized manner.

6.4 Staff Training and Competence

Personnel involved in OBing shall undergo regular training to ensure they are competent in their respective roles and are kept abreast of current best practices and advancements in the field.

6.4.1 Training Programs

All personnel involved in OBing operations shall participate in structured training programs that cover the theoretical and practical aspects of their roles. These programs should be designed to address the specific needs of organoid culture, handling, storage, and data management.

6.4.2 Initial Training

New staff members shall receive comprehensive initial training that includes:

- An overview of organoid biology and its relevance to OBing.
- Detailed procedures for organoid culture, maintenance, and manipulation.
- Safety protocols, including biosafety and biosecurity measures.
- Introduction to QMS and SOPs.

6.4.3 Ongoing Professional Development

Personnel shall be kept informed of developments in the following areas:

- The latest advancements in organoid technology and biobanking.
- Changes in regulatory requirements and ethical guidelines.
- New SOPs and best practices in OBing.

6.4.4 Refresher Courses

Regular refresher courses should be mandatory to reinforce knowledge and skills, ensuring that all staff members maintain a high level of competence in their roles.

6.4.5 Specialized Training

Staff may require specialized training in areas such as:

- Advanced techniques for organoid culture and differentiation.
- Cryopreservation and thawing methods.
- Use of specialized equipment and software for organoid analysis and data management.

6.4.6 Assessment and Certification

Training programs should include a formal assessment process to evaluate staff competence. Certified professionals should be recognized for their expertise in OBing.

6.4.7 Cross-Training

Cross-training initiatives should be encouraged to enhance versatility and ensure that staff members are familiar with multiple aspects of OBing operations.

6.4.8 Mentorship and Supervision

Experienced staff should act as mentors to guide and supervise less experienced colleagues, facilitating knowledge transfer and skill development.

6.4.9 Continuous Learning Culture

OBs should foster a culture of continuous learning within the OB, encouraging staff to actively seek out new information and learning opportunities.

6.4.10 Access to Resources

OBs should ensure that staff have access to resources such as scientific literature, training manuals, and online courses to support their learning and development.

6.4.11 Training Records

OBs shall maintain detailed records of all training activities, including attendance, assessments, and certification, to document staff competence and professional development.

6.5 Sample Handling

SOPs shall detail the procedures for collecting organoid samples, including the type of collection tools, techniques, and environmental conditions to preserve sample viability.

6.5.1 Sample Collection

6.5.1.1 Collection Tools

SOPs shall specify the tools and containers used to collect organoid samples, ensuring they are sterile and appropriate for preserving sample viability.

6.5.1.2 Conditions

SOPs shall define the environmental conditions under which samples should be collected (e.g., temperature, humidity) to avoid degradation.

6.5.1.3 Documentation

SOPs shall include detailed procedures for recording sample metadata, such as source, collection time, and any relevant conditions.

6.5.2 Sample Processing

6.5.2.1 Initial Processing

SOPs shall outline the steps for processing organoid samples immediately after collection to preserve their quality.

6.5.2.2 Handling Procedures

SOPs shall define protocols for handling organoids to prevent contamination or damage, including aseptic techniques and appropriate tools.

6.5.2.3 Processing Conditions

SOPs shall specify temperature and time conditions for processing, such as centrifugation, washing, or any other preparatory steps required.

6.5.2.4 Sample Preservation

SOPs shall provide procedures for preserving organoid samples, including the use of cryoprotectants if freezing, or media if maintaining in culture.

6.5.2.5 Receipt and Acceptance of Externally Obtained Organoid and Source Materials

The OB shall establish and implement documented procedures for the receipt, verification, and acceptance of externally obtained organoid cultures and biological source materials intended for organoid derivation, as applicable to its operational scope.

Acceptance criteria shall address material identity, provenance, traceability, biological characteristics, and suitability for intended use. Verification shall include, as applicable, source tissue information, organoid derivation and culture history, passage number, preservation conditions, available characterization and quality control records, and relevant ethical, legal, and consent restrictions.

The OB shall evaluate the condition and quality of received materials using scientifically justified methods appropriate to their biological characteristics, preservation state, intended use, and associated risks. Additional characterization or testing shall be performed where necessary to establish suitability for acceptance.

Materials awaiting verification or failing established acceptance criteria shall be maintained under controlled conditions to prevent unintended use or distribution. Where immediate processing is necessary to preserve biological integrity, such processing may proceed under documented restrictions without constituting final acceptance.

Acceptance, rejection, restricted-use decisions, and relevant deviations shall be documented and traceable to the corresponding materials or batches.

6.5.3 “Organoid Quality Characterization”

6.5.3.1 Defining Quality Metrics

The OB shall establish and document quality attributes, characterization methods, and acceptance criteria appropriate to the biological origin, characteristics, and intended use of each organoid model. These criteria shall address, as applicable, morphological, molecular, genetic, and functional characteristics, including their stability and reproducibility. Where resemblance to the original or reference tissue is relevant, the OB shall establish scientifically justified criteria to evaluate the degree of similarity while accounting for expected biological variability and model-specific characteristics.

6.5.3.2 “Molecular Characterization”

The OB shall establish and document molecular characterization methods appropriate to the biological origin, characteristics, and intended use of each organoid model. Relevant molecular attributes, including gene and protein expression profiles, genetic markers, and other molecular features, shall be evaluated as applicable to establish organoid identity, differentiation status, and biological fidelity.

Where scientifically relevant, molecular profiles shall be compared with those of the original tissue, appropriate reference tissues, or validated reference datasets. Characterization methods and acceptance criteria shall be scientifically justified, accounting for expected biological variability and intentional genetic or phenotypic modifications. All characterization results shall be documented and maintained as part of the organoid quality records.

The OB shall establish scientifically justified procedures for verifying the biological identity and authenticity of organoid models in relation to their documented source material. Authentication methods and verification intervals shall be appropriate to the organoid model, biological origin, culture history, intended use, and associated risks. Potential misidentification or cross-contamination with other biological cultures shall be investigated, documented, and appropriately addressed.

6.5.3.3 Genetic Stability

The OB shall establish and document procedures for assessing the genetic stability of organoids, considering their biological origin, characteristics, passage history, and intended use. Appropriate methods, including genomic integrity analysis, karyotyping, mutation screening, or other validated molecular techniques, shall be selected based on scientifically justified criteria.

Genetic stability assessments shall distinguish between unintended genetic alterations and expected biological variability, including disease-associated mutations, tumor heterogeneity, and intentional genetic modifications. The OB shall establish appropriate monitoring intervals and acceptance criteria to identify genetic changes that may compromise organoid identity, quality, reproducibility, or suitability for intended use. Assessment results and identified deviations shall be documented, evaluated, and addressed as appropriate.

6.5.3.4 "Functional Validation"

The OB shall establish and document functional validation procedures appropriate to the biological characteristics, developmental stage, and intended use of each organoid model. Relevant functional attributes shall be evaluated using scientifically justified methods, predefined acceptance criteria, and appropriate controls or reference data, where applicable.

Functional stability shall be assessed at defined stages or intervals based on the characteristics of the organoid model, culture conditions, passage history, and associated risks. Where direct functional testing is not applicable or technically feasible, the OB shall document the scientific justification and establish appropriate alternative characterization methods.

All validation results, identified deviations, and their potential impact on organoid quality and suitability for intended use shall be documented and evaluated.

6.5.3.5 Morphological Assessment

The OB shall establish and document morphological assessment procedures appropriate to the biological origin, developmental stage, characteristics, and intended use of each organoid model. Relevant morphological attributes, including size, shape, structural organization, and cellular architecture, shall be evaluated using appropriate methods and scientifically justified acceptance criteria.

Morphological assessments shall account for expected biological heterogeneity, developmental variation, and model-specific characteristics. Deviations from established morphological criteria shall be documented and evaluated to determine their potential impact on organoid quality and suitability for intended use.

Where relevant, morphological findings shall be correlated with molecular or functional characterization results to support the assessment of organoid biological fidelity.

6.5.4 Quality Control (QC)

The OB shall establish and implement documented quality control procedures covering all critical stages of organoid biobanking, including collection, processing, culture, characterization, preservation, storage, and distribution, as applicable.

QC procedures shall incorporate the model-specific quality attributes, assessment methods, and acceptance criteria established under Section 6.5.3. Results shall be evaluated against predefined criteria to determine organoid quality, reproducibility, and suitability for intended use. Samples that do not meet established criteria shall be identified, documented, and managed through appropriate corrective actions or authorized disposition procedures.

6.5.4.1 Key elements of QC

- Sample Integrity and Viability Testing: The OB shall establish procedures for evaluating organoid integrity, viability, and relevant functional characteristics at defined critical stages, including after cryopreservation, thawing, and prolonged storage, where applicable. Assessment methods, monitoring intervals, and acceptance criteria shall be appropriate to the organoid model, preservation method, intended storage duration, and associated risks. Long-term storage stability shall be evaluated using scientifically justified methods, which may include representative sample testing, periodic quality assessments, and relevant storage monitoring records. The OB shall maintain documented evidence supporting the continued suitability of organoids throughout their defined storage period. Changes in biological or functional characteristics shall be evaluated to determine their potential impact on organoid quality and suitability for intended use.
- Equipment Monitoring and Control: Equipment affecting organoid quality shall be qualified, verified, calibrated where applicable, maintained, and monitored in accordance with Section 5.3. Equipment performance and relevant environmental conditions shall be documented, and deviations potentially affecting organoid quality shall be investigated and addressed.
- QC Records and Traceability: QC results, identified deviations, and decisions concerning sample acceptance, rejection, or restricted use shall be documented and traceable to the corresponding organoid samples or batches.
- Contamination Prevention, Detection, and Control: The OB shall establish and implement documented procedures for preventing, detecting, and managing microbial contamination and cross-contamination of

organoid cultures. Appropriate assessment methods, testing intervals, and acceptance criteria shall be established according to the biological characteristics of the organoid model, culture and preservation conditions, intended use, and associated risks. Contamination control shall address relevant critical stages, including organoid establishment, culture expansion, banking, post-thaw recovery, and release, as applicable. Testing for bacterial, fungal, mycoplasma, and other relevant contaminants shall be performed where appropriate. Identified or suspected contamination shall be documented, evaluated, and controlled to prevent unintended use or distribution of affected materials.

6.5.4.2 Audits and Reviews

Rhe OB shall include organoid quality control activities within its internal audit program in accordance with Section 7.11. Audits shall evaluate, as applicable, compliance with established SOPs, implementation of quality control procedures, conformity with predefined acceptance criteria, completeness of QC records, equipment monitoring, and management of deviations.

Audit findings shall be documented, and identified nonconformities shall be addressed in accordance with Section 7.10. Audit outcomes shall contribute to continuous improvement under Section 7.13.

Periodic external audits by independent entities should be conducted to provide additional objective evaluation of QC processes and the effectiveness of the QMS.

6.5.4.3 Corrective Actions

A systematic approach shall be established for addressing any issues identified during the processing, characterization, or storage of organoids. Corrective actions should be focused on both rectifying the issue and preventing future occurrences.

- Root Cause Analysis: Non-conformance events shall be followed by a root cause analysis to identify the source of the problem, whether related to SOP deviations, equipment failures, or human error.
- Preventive Actions: Appropriate preventive actions shall be developed and implemented to ensure that the identified issue does not recur. This may involve updating SOPs, enhancing staff training, or upgrading equipment.
- Issue Documentation and Reporting: Detailed records of issues encountered, as well as corrective and preventive actions taken, shall be maintained. The effectiveness of these actions should be reviewed during subsequent audits to ensure long-term compliance and improvement.
- Competency Checks: OB personnel shall receive regular training on corrective action procedures, and competency assessments shall be conducted to ensure that staff can effectively apply the necessary QC measures.

6.5.5 Alignment with Relevant Standards

The OB shall ensure that SOPs for organoid collection, processing, and characterization comply with the applicable requirements of ISoOR-ISOB. Other recognized standards and scientific guidance may be used as supporting references where relevant, without introducing additional conformity obligations unless required by applicable laws or regulations or expressly incorporated into ISoOR-ISOB.

6.6 “Metrics”

6.6.1 Overview

Metrics refer to the quantitative measures used to assess the quality, functionality, and performance of organoids. These may include size, morphology, viability, growth rate, cumulative growth, “genetic stability”, nutrient and oxygen distribution, and the presence of necrotic regions.

6.6.2 Selection of Metrics

The facility shall identify and select appropriate metrics based on the specific requirements of OBing.

6.6.3 Standardization of Measurement Methods and Audit

6.6.3.1 Overview

Given the challenges associated with measuring organoids, it is crucial to standardize measurement techniques to yield a more accurate representation of organoid size, cellular composition and cumulative growth.

6.6.3.2 Inclusion of Metrics

Metrics should account for not only live cells but also dead cells and those that have contributed to the cumulative growth. This approach addresses the specific characteristics of organoid diversity.

6.6.3.3 Measurement Techniques

6.6.3.3.1 Morphological Evaluation

Morphological evaluation involves quantifying organoid size, shape, and structure using imaging techniques such as microscopy. Appropriate imaging and image analysis methods shall be employed, as applicable, to assess relevant morphological characteristics according to the organoid model and its intended use.

6.6.3.3.2 Functional Measurement

Functional measurement includes evaluating organoid-specific physiological activities, such as secretion, response to stimuli, or drug metabolism. Appropriate assays or functional imaging techniques shall be used, as applicable, to assess relevant physiological activities in relation to the intended use of the organoid model.

6.6.3.3.3 “Molecular Resemblance”

Where molecular resemblance is relevant to the organoid model and its intended use, it shall be assessed using scientifically justified methods, such as gene expression analysis, protein profiling, or DNA sequencing. Comparisons shall be made with appropriate source tissue, reference tissue, or validated reference data, as applicable.

6.6.3.4 Additional Metrics

Facilities should implement metrics evaluating nutrient and oxygen distribution, overall structural integrity, and the presence of any necrotic regions.

6.6.3.5 Validation of Data

6.6.3.5.1 Impact of Device Type on Quantification

The OB shall ensure that the type of device used for organoid quantification does not compromise the accuracy or reproducibility of results. Devices shall be calibrated and validated according to established protocols to ensure the precision and reliability of the data for downstream applications. Measurements used for inter-sample or longitudinal comparisons shall be obtained using the same device or different devices for which measurement comparability has been demonstrated and documented against predefined acceptance criteria, ensuring that observed differences can be distinguished from device-related variability.

6.6.3.5.2 Recommended Techniques and Equipment

The following factors should be considered in selecting the appropriate devices and techniques for quantifying organoids:

- Calibration and Validation: Devices shall be calibrated regularly using reference standards to ensure accurate measurements.
- Performance and Sensitivity: Equipment should meet the required sensitivity thresholds for organoid detection and quantification.
- Reproducibility: The quantification method shall be validated for reproducibility across different devices, operators, and conditions.
- Technological Advancements: The OB may integrate new, validated technologies that improve quantification accuracy, provided their suitability and consistency with established measurement requirements are demonstrated.

6.6.3.6 Regular Audit and Review

The use of metrics and the results derived from them shall be subject to regular audit and review as part of the QMS.

6.6.4 Metrics for Quality Control and Assurance

The OB shall establish criteria for the acceptance or rejection of organoids based on these metrics.

6.6.5 Data Recording and Analysis

All metric data shall be accurately recorded and systematically analyzed. The facility should maintain records that are clear, indelible, and traceable.

6.6.6 Continuous Improvement

The facility shall use metric data to identify areas for improvement and implement necessary changes to enhance the quality of OBing.

6.7 Storage Conditions

Organoids shall be stored under conditions that ensure their viability and stability, with regular monitoring and documentation of storage parameters.

6.7.1 Monitoring

Storage conditions shall be meticulously controlled and continuously monitored to ensure the integrity of the organoids.

6.7.2 Temperature Control

The OB shall establish and maintain storage temperatures appropriate to the organoid type, preservation method, and intended storage duration. Organoids maintained in active culture shall be kept under conditions that support their required growth and metabolic activity. Cryopreserved organoids shall be stored at temperatures demonstrated to maintain their viability and relevant biological characteristics throughout the defined storage period. Refrigerated storage at 2–8°C shall be used only when appropriate for the specific biological material and intended duration. Storage temperature requirements shall be documented, monitored, and verified according to established procedures.

6.7.3 Humidity and Gas Composition

Humidity and atmospheric gas composition shall be controlled and monitored where relevant to maintaining organoid viability, phenotype, and quality. The applicable requirements shall be determined according to the organoid model, preservation method, and storage conditions.

6.7.4 Freezing Process

The cryopreservation of organoids, including their cellular and extracellular matrix (ECM) components where applicable, shall follow documented protocols appropriate to the organoid model, preparation form, and intended use. Cryopreservation methods shall be selected and evaluated to minimize cellular damage and preserve relevant biological, structural, molecular, and functional characteristics according to scientifically justified acceptance criteria.

Specific procedures shall be established for the following preparation forms, as applicable:

- Cryopreservation of Single Cells: Single-cell preparations shall be cryopreserved using methods and cryoprotectants appropriate to the cell type, with controls to minimize cryoinjury and preserve relevant cellular characteristics and recovery potential.
- Cryopreservation of Organoid Fragments or Clusters: Protocols shall address the preservation of cellular composition, structural integrity, viability, and recovery or reaggregation potential, as relevant to the organoid model. Cryoprotectants and preservation conditions shall be selected and controlled according to scientifically justified criteria.
- Cryopreservation of Entire Organoids: Protocols shall address the preservation of three-dimensional organization, cellular viability, and relevant functional characteristics according to the organoid model and intended use. Appropriate cryoprotectants and validated preservation methods, including controlled-rate freezing or vitrification where suitable, may be employed to minimize cryoinjury and support post-thaw recovery.

6.7.5 “Freezing Rate”

6.7.5.1 Controlled Freezing Conditions

Organoids should be frozen under controlled conditions appropriate to their biological characteristics and the selected cryopreservation method. Cooling rates and related parameters should be established to minimize cryoinjury and maintain acceptable post-thaw viability and functionality. Different freezing approaches, including controlled-rate freezing and vitrification, may be applied according to the organoid type and scientifically justified preservation requirements.

6.7.5.2 Freezing Protocol Documentation

Detailed cryopreservation protocols shall be documented and followed, specifying the preservation method, equipment, cryoprotectants, and relevant operating parameters, including cooling rates, temperature profiles, and exposure times, as applicable. Procedures shall establish appropriate acceptance criteria and controls to ensure reproducibility and suitability for the intended organoid model.

6.7.6 Thawing Process

6.7.6.1 Controlled Thawing Conditions

Organoids, whether cryopreserved as single cells, fragments/clusters, or entire structures, shall be thawed under controlled conditions appropriate to the organoid model and cryopreservation method. Thawing procedures shall be designed to preserve cell viability, structural integrity, and relevant functional characteristics while minimizing ice recrystallization, osmotic stress, thermal injury, and other sources of cellular damage.

The thawing temperature, rate, and duration shall be established according to scientifically justified protocols. Rapid thawing, including the use of a 37°C water bath, may be employed where appropriate, while alternative methods shall be used when required by the specific preservation protocol. Following thawing, the material shall be handled under defined conditions to support cellular recovery and minimize damage.

6.7.6.2 Thawing Protocol Documentation

Detailed thawing protocols shall be documented and followed, specifying the thawing method, equipment, temperature, duration, and handling procedures appropriate to the organoid model. Where applicable, protocols shall include cryoprotectant dilution or removal, transfer to suitable recovery media, and post-thaw culture conditions. Acceptable operating parameters and criteria for evaluating post-thaw recovery shall be established to ensure consistency and reproducibility.

6.7.6.3 Post-Thaw Culture and Recovery

Following the thawing process, organoids should be cultured under optimized conditions to promote recovery and growth. This includes using pre-warmed culture media and appropriate supplements that support cell viability. Monitoring of the organoids during the recovery phase should be part of the standard protocol, ensuring that they meet predefined criteria for viability, morphology, and function.

6.7.6.4 Post-Thaw Viability Assessment

The OB shall establish and document procedures for assessing post-thaw viability and recovery using scientifically justified methods appropriate to the organoid model, preservation method, and intended use.

Viability shall be evaluated using suitable methods, such as membrane integrity assays, metabolic activity measurements, or other validated approaches. Structural integrity, functional recovery, and molecular characteristics shall be assessed where relevant to the organoid model and established quality requirements.

Assessment methods, acceptance criteria, and results shall be documented. Deviations from established criteria shall be evaluated to determine their potential impact on organoid quality and suitability for intended use.

6.7.6.5 Documentation and Record Keeping

Accurate records of the thawing process, including any deviations from the standard protocol, should be maintained. This documentation should be integrated into the OB’s IMS to ensure traceability and to support compliance with regulatory and quality requirements.

6.7.6.6 Alarm Systems Surveillance

Real-time monitoring systems should be in place to continuously track storage conditions, with automated alarms to alert personnel of any deviations from the set parameters.

6.7.6.7 Data Recording and Traceability

All storage parameters, including temperature, humidity, and gas composition, shall be recorded and documented for traceability and quality assurance purposes.

6.7.6.8 Periodic Quality Assessments

Regular quality assessments shall be conducted to evaluate the effectiveness of storage conditions in maintaining organoid viability and functionality.

6.7.6.9 Incorporation of Contamination Management Procedures

The OB shall establish and implement procedures for preventing, detecting, and managing contamination associated with thawed organoid material. Testing for bacterial, fungal, mycoplasma, endotoxin, or other relevant contamination shall be performed as appropriate to the biological material, preservation conditions, intended use, and associated risks. Suitable detection methods, testing frequency, acceptance criteria, and corrective actions shall be defined and documented to ensure the microbiological quality and suitability of organoid cultures.

6.7.7 Storage Capacity and Organization

The OB's storage capacity should be planned to accommodate the current and projected future needs, with an organized system for efficient sample retrieval and inventory management.

6.7.8 Disposal and Decommissioning

Guidelines for the ethical and secure disposal of organoids that are no longer needed or that do not meet quality standards shall be established.

6.7.9 Storage and Handling Training

All personnel involved in the storage and handling of organoids shall be trained on the importance of storage conditions and the procedures for maintaining them.

6.8 Staining Procedures

6.8.1 Standardization of Staining Protocols

All staining procedures for organoid samples shall follow standardized protocols to ensure consistent, reproducible, and high-quality results. These protocols should be clearly defined and validated for various types of staining techniques used in organoid characterization, including but not limited to histological, immunohistochemical, and fluorescent staining.

6.8.2 Selection of Staining Agents

The selection of staining agents (e.g., dyes, antibodies, fluorescent markers) shall be based on their ability to effectively and specifically bind to the target structures within the organoid. All reagents shall be:

- Validated for Specificity and Sensitivity: Staining agents shall be proven to provide clear and reliable differentiation of organoid components without cross-reactivity.
- Compatible with the Organismal Model: Staining reagents should be compatible with the species and specific characteristics of the organoids being studied.

6.8.3 Consistency Across Batches

Staining protocols shall also be consistent across all batches of organoids to ensure comparability of data. Deviations in staining results due to variations in reagent lot numbers, processing conditions, or operator technique should be minimized. Any changes in reagents, equipment, or procedures shall be documented and validated.

6.9 “Passaging” of Organoids

6.9.1 Impact on Molecular Characteristics

The OB shall evaluate and document the impact of passaging on the molecular and functional properties of organoids. Passaging, which involves transferring organoids to new culture conditions for continued growth, may result in the loss of certain molecular characteristics inherent to the original organoid. The OB shall ensure that the potential effects of passaging on the reproducibility and consistency of research or clinical applications are assessed and accounted for. The OB shall implement measures to mitigate any adverse impact on organoid integrity during passaging to maintain the fidelity of the model for its intended applications.

6.9.2 Determination of Passage Limits

The OB shall establish and document scientifically justified passage limits or acceptable passage ranges for each organoid model, as appropriate to its biological characteristics, culture conditions, and intended use. These limits shall be based on available experimental evidence and relevant quality attributes, including molecular, genetic, morphological, and functional stability, as applicable.

Where a fixed maximum passage number cannot be scientifically established, continued passaging may be permitted under documented monitoring and predefined acceptance criteria. Organoids exceeding established passage limits or exhibiting changes that may compromise their quality shall undergo appropriate reassessment before further use or distribution.

6.9.3 Documentation and Monitoring

OBs shall maintain records of the passage number for each organoid culture, including the specific methods and reagents used. These records will help ensure traceability and allow for the evaluation of the effect of passaging on the organoid's integrity. Monitoring should be performed at regular intervals to identify any signs of molecular drift or loss of function, ensuring the quality of the organoid bank remains high.

6.9.4 Standardization of Passaging Procedures

Standardized passaging protocols should be implemented and followed to minimize variation in organoid quality across different batches. These protocols should include recommendations on culture conditions, passaging techniques, and methods for assessing the molecular and functional status of organoids after each passage. Regular reviews of these protocols should be conducted to ensure continued efficacy in preserving organoid characteristics.

6.10 Molecular Profiling

6.10.1 Purpose and Scope

Molecular profiling provides methods for characterizing the genetic and molecular properties of organoids. Its application shall be determined according to the biological characteristics of the organoid model, relevant quality attributes, and intended use.

Where scientifically justified, molecular profiling shall support the assessment of organoid identity, molecular characteristics, biological fidelity, and suitability for intended applications, including disease modeling, personalized medicine, quality control, and functional validation.

6.10.2 Donor and Tissue Characterization

Where donor-source tissue is relevant and available, the OB shall use appropriate molecular profiling methods to document genetic characteristics that may influence organoid behavior.

6.10.3 Disease Modeling and Personalized Medicine

For organoids derived from diseased tissues, the OB shall characterize disease-associated molecular features relevant to the model and intended use, including genetic alterations where applicable. Where clinical data are relevant and available, the relationship between these features and disease pathology or clinical outcomes shall be evaluated and documented.

6.10.4 Quality Control and Functional Validation

Where scientifically justified by the organoid model and its intended use, molecular profiling shall be performed to assess relevant genetic, molecular, and phenotypic characteristics over time, accounting for expected biological variability, disease-associated alterations, and intentional modifications.

Appropriate profiling methods, assessment intervals, and acceptance criteria shall be established according to the relevant quality attributes of the organoid model. Where applicable, molecular findings shall support the evaluation of biological fidelity against source tissue, appropriate reference material, or validated reference data.

Deviations from established acceptance criteria shall be documented, evaluated for their potential impact on organoid quality and suitability for intended use, and addressed in accordance with established SOPs.

6.10.5 Cryopreservation Impact Assessment

The OB shall assess and document the impact of cryopreservation and thawing on organoid quality and biological characteristics relevant to their intended use. Assessment methods and acceptance criteria shall be established according to the organoid model, preservation method, and associated risks.

Post-thaw viability and recovery shall be evaluated using appropriate biological or functional assessment methods. Molecular profiling shall be performed where scientifically justified to evaluate preservation-associated changes in genetic or molecular characteristics. Identified deviations shall be documented and assessed to determine their potential impact on organoid quality, stability, and suitability for intended use.

Note: For additional requirements related to cryopreservation and thawing, refer to Sections 6.7.4, 6.7.5, and 6.7.6.

6.10.6 Genome Editing Verification

For organoids subjected to genome editing, molecular profiling shall confirm the successful introduction of genetic modifications. The OB shall document these changes and their implications for the organoid's function and relevance to research objectives.

6.10.7 Inter- and Intra-Tumor Heterogeneity

For cancer-derived organoids, the OB shall consider inter- and intra-tumor heterogeneity when establishing characterization procedures appropriate to the organoid model and its intended use.

Relevant genetic and molecular variability shall be assessed using scientifically justified methods, including molecular profiling where applicable. Assessments shall consider available source tissue information, expected biological variability, and potential changes introduced during organoid derivation, culture, or passaging.

The OB shall document the characterization results and any identified limitations in the representation of tumor heterogeneity. Where relevant and supported by available evidence, the potential implications for disease modeling, tumor biology, and treatment-response studies shall be evaluated and documented.

6.11 Mimicry of Organ Fidelity and Functions

The OB shall establish procedures to assess and validate structural and functional characteristics of organoids relevant to their intended use. These procedures shall ensure that organoid models are evaluated against scientifically justified criteria to determine their suitability for downstream applications.

6.11.1 Structural and Functional Fidelity

Organoids shall be evaluated for relevant structural and functional attributes in accordance with their biological characteristics, developmental stage, and intended use. This includes, as applicable:

- Cellular Composition: Assessment of the presence, identity, and distribution of cell types relevant to the organoid model, accounting for expected biological heterogeneity and intentional modifications.
- Architectural Organization: Assessment of tissue organization, including the spatial arrangement of cells, tissue layers, and relevant microenvironmental structures, according to the characteristics and intended use of the model.
- Functional Outputs: Evaluation of relevant physiological activities, such as secretion, metabolite production, electrical activity, or response to stimuli, using scientifically justified methods and acceptance criteria.

6.11.2 Advanced Validation Techniques

Advanced validation techniques should be considered according to the complexity, characteristics, and intended applications of the organoid model. These may include:

•Molecular Characterization: Proteomics, metabolomics, and other appropriate molecular methods to evaluate relevant biological attributes and, where scientifically justified, compare them with reference tissues or validated datasets.

•Functional Assays: Specialized assays to assess relevant functional properties, such as electrical activity in neuronal organoids or transport functions in kidney organoids, where applicable.

•Comparative Analysis: Comparison with appropriate reference tissues, biological models, or validated reference data to assess relevant structural, molecular, or functional characteristics where such comparisons are scientifically justified.

6.11.3 Fidelity Assessment

The OB shall establish monitoring procedures and assessment intervals appropriate to the organoid model, culture conditions, and intended use. Relevant structural and functional characteristics shall be evaluated against scientifically justified acceptance criteria, accounting for expected biological variability and intentional modifications.

Deviations that may compromise organoid quality, biological characteristics, or suitability for intended use shall be documented and evaluated. Appropriate corrective actions shall be implemented where established acceptance criteria are not met.

6.11.4 Documentation and Reporting

All procedures, assessments, and validation results shall be thoroughly documented to ensure reproducibility and transparency. Data related to organoid fidelity should be stored and accessible to relevant stakeholders for future reference, including researchers, OB staff, and regulatory authorities.

6.12 Emergency Protocols

Emergency protocols shall be developed to address equipment failure or power outages, ensuring the rapid response and minimal impact on stored organoids.

6.12.1 Equipment Failure Response

Emergency protocols shall include detailed procedures for addressing equipment failure, such as the malfunction of cryogenic storage units or temperature monitoring systems. Immediate actions should involve transferring organoids to backup storage units that have been pre-validated to maintain the required storage conditions. All personnel shall be trained to recognize and respond to equipment alarms, ensuring that organoids are not exposed to temperature fluctuations that may compromise their viability.

6.12.2 Power Outage Contingency Plans

A robust contingency plan shall be in place to manage power outages. This plan should include the availability of backup power sources, such as generators or uninterruptible power supplies (UPS), which are capable of maintaining critical storage conditions until normal power is restored. The protocol should also include clear instructions on how to monitor storage conditions during a power outage, and the procedure for prioritizing organoid transfers if extended outages occur.

6.12.3 Emergency Training and Drills

Regular training sessions and emergency drills should be conducted to ensure all personnel are prepared to execute the emergency protocols effectively. This training should cover the identification of potential risks, immediate response actions, and the use of backup systems. Personnel shall be familiar with the location and operation of emergency equipment, as well as the communication plan for notifying key stakeholders during an emergency.

6.12.4 Emergency Communication Plan

An emergency communication plan shall be established, outlining the steps for notifying key personnel, stakeholders, and emergency services in the event of a crisis. This plan should include up-to-date contact information for all relevant parties and clearly define the roles and responsibilities of each team member during an emergency.

6.12.5 Documentation and Review

All emergency responses and actions taken during equipment failure or power outages shall be documented in detail. This documentation should be reviewed regularly as part of the OB's QMS to identify any areas for improvement in the emergency protocols. Regular reviews and updates to the emergency protocols ensure they remain effective and aligned with the latest best practices and technological advancements.

6.12.6 Risk Mitigation and Preventive Measures

As part of the emergency protocols, preventive measures should be implemented to minimize the risk of equipment failure or power outages. This includes regular maintenance and testing of storage units, backup systems, and alarms, as well as conducting risk assessments to identify potential vulnerabilities in the OB's infrastructure. These measures help to ensure the continuous protection of stored organoids, even in unforeseen circumstances.

6.13 Data Management

Robust data management practices shall be employed to handle sensitive information related to donors, samples, and research data, ensuring data security and confidentiality.

6.14 Risk Management

A proactive risk management approach shall be adopted to identify, assess, and mitigate potential risks associated with OBing operations.

6.15 Ethical Considerations

Ethical principles shall guide all aspects of OBing, with particular attention to informed consent, privacy, and the responsible use of biological materials.

6.16 Distribution and Access

Clear policies and procedures shall govern the distribution and access to organoids, ensuring equitable, transparent, and controlled allocation for authorized research, clinical, or therapeutic purposes, as applicable. Distribution shall comply with relevant ethical, legal, regulatory, and contractual requirements.

6.16.1 Policy Development

A clear and comprehensive policy framework shall be established to govern the distribution and access to organoids. This framework shall ensure that the allocation of organoids is transparent, equitable, and aligns with the ethical principles and objectives of the OB. The policy should address criteria for eligibility, priority, and access, taking into account the scientific merit, intended application, potential impact, associated risks, and relevant ethical and regulatory requirements.

6.16.2 Request and Approval Process

A standardized process for requesting access to organoids shall be implemented. Requests shall be evaluated and authorized by designated competent personnel according to established criteria, considering the intended use, scientific justification, ethical requirements, feasibility, and associated risks. Independent scientific, ethical, or regulatory review shall be obtained where required by applicable regulations, institutional policies, or the nature and risk of the proposed application.

Before distribution, the OB shall verify that the organoid material meets the applicable identification, traceability, quality control, and release criteria established for its intended use. Relevant consent restrictions, ethical authorizations, and contractual conditions shall also be verified. Samples that do not meet established requirements shall not be released unless a documented, scientifically justified decision authorizes their distribution for a clearly defined restricted purpose, where permitted by applicable requirements.

All approval, release, rejection, and restricted-use decisions shall be documented and traceable to the corresponding organoid samples or batches.

6.16.3 Transparency and Accountability

The OB shall maintain transparency in its distribution and access practices by documenting and publicly disclosing the criteria used for decision-making. Records of all requests, approvals, and distributions shall be maintained, with regular audits conducted to ensure accountability and adherence to established policies.

6.16.4 MTAs

Before the distribution of organoids, MTAs shall be executed between the OB and the recipient institution. These agreements shall clearly define the terms of use, including intellectual property rights, confidentiality, and reporting obligations. MTAs shall also stipulate that organoids are to be used exclusively for the approved purposes and that any deviations require prior approval from the OB.

6.16.5 Ethical Considerations

The distribution and access policy shall incorporate ethical considerations, ensuring that the use of organoids aligns with the consent provided by donors and respects the cultural and societal values of the communities involved.

6.16.6 Transparency Tracking

The OB shall regularly monitor the distribution and access processes to ensure they remain fair, transparent, and aligned with the OB's mission. Periodic reviews shall be conducted to update policies and procedures in response to evolving scientific, ethical, and legal standards.

6.16.7 Transport and Shipment of Organoids

The OB shall establish and implement documented procedures for the packaging, transportation, shipment, and receipt of organoid materials, as applicable to its operational scope.

Packaging methods and transportation conditions shall be appropriate to the organoid model, preservation state, intended use, and associated risks. Critical parameters, including temperature, transport duration, and handling requirements, shall be defined and controlled according to scientifically justified criteria. Packaging and transportation arrangements shall be qualified or verified, as appropriate, to demonstrate their suitability for maintaining organoid quality and integrity.

Each shipment shall be traceable through appropriate identification, dispatch, transportation, and receipt records. The OB shall establish procedures for verifying shipment conditions upon receipt, identifying deviations, and assessing their potential impact on organoid quality and suitability for intended use.

Transportation deviations that may compromise organoid quality shall be documented, investigated, and addressed through appropriate corrective actions. Responsibilities for shipment preparation, transportation, monitoring, and receipt shall be clearly defined between the parties involved.

6.17 Reporting of Organoid Culture Results

6.17.1 General Reporting Requirements

The OB shall ensure that reports of organoid characterization, culture performance, and quality control results are accurate, traceable, and appropriate to the organoid model and intended use. Reported information shall be sufficiently clear and complete to support the interpretation of organoid characteristics, quality, and suitability for intended applications.

6.17.2 Examination and Review of Results

Organoid characterization and quality control results shall be reviewed by designated competent personnel before reporting. The review shall verify the accuracy, completeness, traceability, and conformity of results with established assessment methods and acceptance criteria.

Reported deviations or limitations that may affect organoid quality, reproducibility, or suitability for intended use shall be appropriately documented and communicated.

6.17.3 Notification and Documentation Procedures

The OB shall establish procedures for notifying relevant users or recipients of significant findings that may affect the identity, quality, integrity, or suitability for intended use of organoid materials previously distributed or reported.

Such findings may include contamination, misidentification, significant deviations from established quality criteria, or newly identified limitations affecting the intended application.

Notifications shall be documented, including the nature of the finding, affected organoid materials or batches, recipients notified, and any recommended actions or restrictions.

6.17.4 Special Considerations for Reporting:

- With user agreement, simplified or preliminary reports may be provided, but it shall be clear that the initial findings are preliminary.
- Oral communications of results shall be documented and verified for accuracy.

6.17.5 Automated Reporting Systems

If automated systems are used for result selection, review, release, and reporting, the OB shall establish procedures to ensure their accuracy and reliability. Criteria for automated processes shall be validated, approved, and regularly reviewed.

6.17.6 Content of Organoid Culture Reports

The OB shall define the information required in organoid characterization and quality reports according to the organoid model, activities performed, and intended use.

Reports shall include, as applicable, organoid identification, biological origin, relevant derivation and culture history, passage number, preservation status, characterization results, quality control findings, and applicable acceptance criteria.

Relevant limitations, deviations, and restrictions affecting the interpretation or use of the organoid materials shall be clearly documented. Reported information shall remain traceable to the corresponding organoid samples or batches and associated quality records.

6.17.7 Amendments to Reported Results

Any amendments to results shall follow a clear and documented procedure that ensures transparency and accuracy. Users shall be notified of any changes, with the reason for the amendment recorded.

6.18 Audit and Compliance

Regular audits shall be conducted to assess compliance with operational criteria and identify areas for improvement.

6.19 Continuous Improvement

The OB shall be committed to a culture of continuous improvement, leveraging feedback, audit findings, and research advancements to enhance operational efficiency and quality.

7 “Quality Assurance” (QA)

7.1 Overview

The QA framework is integral to ensuring that all operations within the OB adhere to the highest standards of quality, reliability, and ethical conduct. The framework is designed to maintain the integrity of processes and outcomes, ensuring consistent delivery of high-quality OBing services.

7.2 QMS

A comprehensive QMS shall be established and maintained in accordance with the applicable requirements of ISoOR-ISOB. Other relevant international standards may be used as supporting references for QMS development and implementation but shall not impose additional conformity requirements unless explicitly incorporated into ISoOR-ISOB or required by applicable laws or regulations. This QMS shall focus on QA, serving as the foundation for continuous improvement and risk management within the OB.

The QMS will encompass the following requirements:

- Continuous Improvement: Systems and processes that foster a culture of ongoing enhancement based on data and feedback.
- Risk Management: Proactive identification and mitigation of risks to ensure QA throughout operations.
- Additionally, the QMS shall ensure that QA practices are embedded in all processes and that performance metrics are utilized to drive quality improvements and accountability. Emphasis will be placed on integrating these practices to uphold excellence and reliability in outcomes.

7.3 Quality Policy

A formally documented Quality Policy shall be established, articulating the OB's commitment to maintaining excellence in quality, adhering to ethical standards, and complying with applicable regulatory requirements. The Quality Policy shall be communicated to all stakeholders and reviewed periodically for relevance and effectiveness.

7.4 Quality Objectives

Quality Objectives shall be defined in alignment with the OB's overall mission and goals. These objectives shall be Specific, Measurable, Achievable, Relevant, and Time-bound (SMART) to provide clear guidance and a basis for performance evaluation across all biobanking activities.

7.5 Quality Planning

Comprehensive Quality Plans shall be developed and implemented for all critical stages of the OBing process, including procurement, processing, storage, and distribution of organoids. These plans shall detail the steps necessary to achieve the defined Quality Objectives and mitigate potential risks.

7.6 Responsibilities and Resources

The OB shall ensure the clear assignment of responsibilities and the provision of adequate resources, including trained personnel, facilities, equipment, and materials, to support the effective implementation of the QMS and achieve the Quality Objectives.

7.7 Process Control

All processes within the OB shall be controlled and, where necessary, validated to ensure they consistently produce organoids that meet established quality criteria.

7.8 Evidence of Conformity

The OB shall establish and maintain documented procedures to demonstrate conformity with the applicable requirements of ISoOR-ISOB. Objective evidence shall be available to verify the implementation and effectiveness of relevant quality, technical, operational, ethical, and management processes.

Evidence of conformity shall include, as applicable, controlled procedures, competence records, validation and verification results, quality control records, traceability information, monitoring results, internal audit findings, and records of nonconformities and corrective actions.

For requirements determined to be non-applicable, the OB shall maintain a documented justification consistent with its declared operational scope. Assessment criteria and acceptance limits shall be defined and scientifically justified where required, ensuring that conformity decisions are based on verifiable evidence rather than subjective interpretation.

7.8.1 Establishing Measurement Criteria

Measurement criteria shall be established to reflect the quality standards required for OBing, encompassing all critical aspects of the process.

7.8.2 Calibration and Maintenance

A strict schedule for the calibration and maintenance of all “monitoring and measurement devices” shall be implemented to ensure accuracy and reliability.

7.8.3 Data Collection and Analysis

Standardized procedures for data collection and analysis shall be created to ensure consistency, transparency, and the identification of trends or anomalies.

7.8.4 Corrective and Preventive Actions

Data from monitoring activities shall be used to identify the need for corrective and preventive actions, ensuring ongoing process improvement.

7.9 Data Integrity and Security

The OB shall maintain the integrity and security of all data through documented and controlled processes and information and data management systems that are qualified or validated, as appropriate for their intended use, in accordance with 5.3.6.5. These controls shall ensure the accuracy, confidentiality and availability of data.

7.10 “Nonconformity” and Corrective Action

A procedure for the identification, investigation, and correction of nonconformities shall be established, along with preventive measures to avoid recurrence.

7.11 Internal Audits

Regular internal audits shall be conducted to verify compliance with the QMS and identify opportunities for improvement.

7.12 Management Review

Top management shall periodically review the QMS to ensure its continued suitability, adequacy, and effectiveness in achieving the OB's Quality Objectives.

7.13 Continuous Improvement

The OB shall be committed to continuous improvement, utilizing quality data and feedback to enhance processes and outcomes.

7.14 Documentation and Record Keeping

Documentation and record-keeping practices shall be established to provide a reliable account of all activities, ensuring transparency, traceability, and compliance with regulatory standards.

7.14.1 Documentation Control

A system for controlling all documentation shall be established to ensure that documents are current, accessible, and protected from unauthorized changes.

7.14.2 Record Maintenance

Records shall be maintained in a clear, complete, and indelible manner, stored to prevent loss or deterioration.

7.14.3 Confidentiality and Security

Documentation and records shall be protected with security measures to prevent unauthorized access or tampering.

7.15 Lifecycle Documentation Tracking and Conditions Management

7.15.1 General Requirements

All organoid samples shall be thoroughly documented and traceable throughout their lifecycle. A robust system shall ensure data reliability and reproducibility to meet the needs of clinical and research applications.

7.15.2 “Barcoding Systems” for Organoid Sample Identification

7.15.2.1 Essentials

The OB shall establish and maintain a standardized identification system to ensure accurate identification and traceability of organoid samples throughout their lifecycle. The system shall:

- Comply with applicable national, regional, and local regulatory requirements.
- Assign each organoid sample a unique, persistent identifier linked to its origin, processing history, storage location, and associated records.
- Ensure that identifiers remain legible, accurate, and traceable under the applicable processing, handling, and storage conditions.
- Support compatibility with electronic information management systems and automated biobanking technologies, where applicable.

Barcoding systems, including linear and two-dimensional formats, may be used for sample identification. Alternative identification methods are acceptable provided they demonstrate equivalent reliability, traceability, and protection against identification errors.

7.15.2.2 Specifications

BThe OB shall establish documented specifications for its selected identification method, including identifier uniqueness, durability, readability, verification, and traceability.

Where barcoding systems are used, protocols shall include:

- Use of durable labels suitable for the applicable storage conditions, including cryogenic temperatures where relevant.
- Selection of barcode formats appropriate to the required identification and data-management functions.
- Implementation of QA measures to verify barcode readability, accuracy, and durability throughout the sample lifecycle.

7.15.3 Comprehensive Record-Keeping

7.15.3.1 Details

At every stage of the organoid sample lifecycle, detailed records shall be maintained, including:

- Metadata on the organoid's origin, such as donor information (adhering to ethical guidelines) and cell line characterization.
- Documentation of critical processing steps, such as derivation, passaging, cryopreservation, and thawing.
- Time-stamped records of environmental conditions and any deviations.

7.15.3.2 Platforms

Record-keeping systems may be paper-based, electronic, or a combination of both, provided that they are controlled, secure, traceable and appropriate for their intended use, in accordance with 3.4.2, 5.3.6 and 7.14. Where electronic platforms are used, they shall be capable of:

- Supporting long-term storage and efficient retrieval of records for analysis and audits.
- Enabling data sharing in compliance with regulatory and ethical frameworks.

7.15.4 Standardized Guidelines for Barcoding in OBing

7.15.4.1 Guidelines

Where barcoding systems are used, barcoding processes shall adhere to standardized guidelines that:

- Protect sample confidentiality and data integrity.
- Align with applicable national, regional, or local regulations.
- Ensure compatibility with cryopreservation protocols to maintain barcode functionality under ultra-low temperatures, where applicable.

7.15.4.2 Training

Personnel responsible for sample identification shall receive training appropriate to the identification systems and procedures used by the OB. Where barcoding systems are implemented, training shall include applicable barcode labeling, handling, verification, and traceability procedures.

7.16 Ethical Considerations

Ethical considerations shall be integrated into the QA system, ensuring respect for donor rights, informed consent, and responsible use of organoids in research.

7.17 Regulatory Compliance

Compliance with all relevant regulatory requirements and guidelines shall be ensured throughout all aspects of OBing operations.

Annexes: Standard Operating Procedures (SOPs)

Annex A: Development of NUT Carcinoma Organoids (The full document is available for separate download from the ISoOR-ISOB repository at www.isoor.org).

List of Abbreviations:

AI: Artificial Intelligence

ECM: Extracellular Matrix

ELISA: Enzyme-Linked Immunosorbent Assay

FISH: Fluorescent In Situ Hybridization

GLP: Good Laboratory Practice

IMS: Information Management System

IP: Intellectual Property

ISoOR: International Society of Organoid Research

ISoOR-ISOB: ISoOR-International Standard for Organoid Biobanking

LIMS: Laboratory Information Management System

MTA: Material Transfer Agreement

OB: Organoid Biobank

OBing: Organoid Biobanking

PCR: Polymerase Chain Reaction

QA: Quality Assurance

QC: Quality Control

QMS: Quality Management System

SMART: Specific, Measurable, Achievable, Relevant, and Time-bound

SOP: Standard Operating Procedure

Glossary of Terms:

- **Access Agreements:** Formal documents that define who is allowed to access organoid samples and related data, under specific conditions and purposes. These agreements are critical for ensuring that ethical standards and informed consent are met.
- **Adaptive AI System:** An AI system designed to modify its behavior or performance after deployment through learning or other adaptation mechanisms. Routine software updates, configuration changes or maintenance activities do not, by themselves, constitute adaptive learning.
- **AI Incident:** An event involving an AI system that results in an actual adverse impact on safety, privacy, security, data integrity, conformity or other relevant interests.
- **AI Near Miss:** An event involving an AI system that could reasonably have resulted in such an adverse impact but did not, because it was detected, prevented or otherwise did not progress to an adverse outcome.
- **Artificial Intelligence (AI) System:** A machine-based system that, for explicit or implicit objectives, infers from inputs how to generate outputs such as predictions, classifications, recommendations, decisions or content. AI systems may vary in their levels of autonomy and adaptiveness and may be developed internally, acquired from or operated by third parties, or embedded in other systems used by an OB.
- **Audit Trails:** Records that document the history of changes made to data or documents. These include timestamps, the identity of the person who made the change, and the reasons for those changes, essential for maintaining data integrity and regulatory compliance.
- **Barcoding System:** A method for labeling and tracking organoid samples using unique identifiers (e.g., barcodes or alphanumeric codes), ensuring proper documentation and traceability throughout the biobanking process.
- **Biochemical Consistency:** The uniformity in the composition of reagents, culture media, and other materials used in organoid culture. Ensuring consistency is vital for maintaining reproducibility and reliable outcomes in research.
- **Biocompatibility:** The ability of materials, such as extracellular matrix (ECM) components, to be used in contact with biological systems without causing harmful effects such as toxicity or immune rejection.
- **Biological Drift:** A change over time in the biological characteristics of an organoid culture or associated biological material that may result from passage, culture conditions, differentiation, selection, material variability or other biological or technical factors and that may affect quality, reproducibility or AI-system performance.
- **Biological Heterogeneity:** Variation in biological, morphological, molecular or functional characteristics among organoids or organoid populations arising from intrinsic biological differences or relevant culture and experimental conditions.
- **Consequential AI-Assisted Activity:** An AI-assisted activity that may materially affect quality, access, distribution, safety, donor rights, research conclusions or reporting.
- **Contamination:** The unintended presence of biological, chemical or other extraneous material in an organoid culture or associated biological material that may affect quality, biological characteristics, reproducibility or AI-system performance.
- **Cryopreservation:** A technique for preserving organoids and cells at ultra-low temperatures (typically between -196°C to -150°C), enabling long-term storage while maintaining viability and functionality.
- **Data Drift:** A material change in the characteristics, quality, distribution, source population or context of data used by an AI system that may affect performance or risk.
- **Data Integrity and Security:** Protecting data related to organoids and donors, ensuring it is accurate, confidential, and accessible, in compliance with international data protection regulations.
- **Data Management:** The practice of handling and storing sensitive information associated with donors, organoid samples, and research data, ensuring its security, confidentiality, and proper organization.
- **Data Protection and Privacy:** Measures and protocols designed to safeguard the privacy and confidentiality of personal and sensitive data associated with organoid samples, in alignment with data protection laws.
- **Equity:** The principle of ensuring fair and equal access to resources, opportunities, and benefits for all stakeholders in organoid biobanking activities.

- **Ethical Compliance:** Adhering to established ethical standards and regulatory requirements, particularly concerning informed consent, donor confidentiality, and responsible use of biological materials.
- **Extracellular Matrix (ECM):** A complex network of proteins and molecules that provide structural and biochemical support to organoids, facilitating their growth and maintenance in culture.
- **Freezing Rate:** The controlled rate at which organoids are cooled during cryopreservation to prevent ice crystals from damaging cellular structures, thereby preserving the sample's viability.
- **Functional Validation:** The process of evaluating relevant functional characteristics of an organoid model against scientifically justified criteria appropriate to its biological characteristics, developmental stage, and intended use.
- **Generative AI System:** An AI system that produces new content in response to inputs or instructions.
- **Genetic Stability:** The maintenance of genetic characteristics within scientifically justified acceptance criteria over time, accounting for expected biological variability, disease-associated alterations, and intentional genetic modifications.
- **Good Laboratory Practice (GLP):** Refers to a set of principles intended to ensure the quality, integrity, and reliability of non-clinical laboratory studies, particularly those related to the safety evaluation of chemicals and pharmaceuticals. GLP standards govern the organization, processes, and conditions under which laboratory studies are planned, performed, monitored, recorded, and reported.
- **Informed Consent:** The procedure by which participants or donors provide explicit permission for the use of their biological materials, with a clear understanding of the risks, benefits, and purpose of the research.
- **Intellectual Property (IP) Rights:** Legal protections for innovations and discoveries resulting from organoid research, including patents, copyrights, and trademarks, which define the ownership of these discoveries.
- **Legal Ownership:** The legal rights and responsibilities regarding organoids and their associated data, established through formal agreements and compliant with applicable laws.
- **Material Change:** A change to an AI system, data, intended purpose, provider or operating context that may affect validity, performance, risk or conformity.
- **Material Transfer Agreement (MTA):** Legal agreements that define the terms of use and sharing of organoids, addressing intellectual property, confidentiality, and reporting requirements.
- **Metrics:** Quantitative measures used to assess the quality, functionality, and performance of organoids, including parameters such as viability, growth rate, morphology, and genetic stability.
- **Molecular Characterization:** The analysis of relevant molecular attributes, including gene expression, protein profiles, and genetic markers, to establish organoid identity, biological characteristics, and suitability for its intended use. Comparison with reference tissues or datasets is performed where scientifically relevant.
- **Molecular Resemblance:** The extent to which organoids replicate the molecular profile of the original tissue, which is assessed through techniques like gene expression analysis and DNA sequencing.
- **Monitoring and Measurement Devices:** Tools and equipment used to monitor and record important parameters such as temperature, humidity, and gas composition during the storage and handling of organoid samples.
- **Nonconformity:** The failure of a process or product to meet the required quality or regulatory standards, often necessitating corrective action.
- **Organoid:** A three-dimensional cellular model derived from stem cells, progenitor cells, or tissue-derived cells, typically exhibiting self-organization and reproducing selected structural, cellular, molecular, or functional characteristics of a specific tissue or organ. The extent of biological resemblance depends on the organoid model, its developmental stage, and intended use.
- **Organoid Biobanking:** The practice of collecting, storing, and managing organoids for research, clinical, and therapeutic purposes, ensuring their viability, integrity, and traceability.
- **Organoid Culture:** The process of cultivating organoids in vitro, using specific media and environmental conditions to support their growth and maintain their functional capabilities.
- **Organoid Quality Characterization:** The systematic evaluation of an organoid model's morphological, molecular, genetic, and functional attributes, as applicable, against scientifically justified quality criteria to determine its identity, reproducibility, and suitability for intended use.

- **Passaging:** The process of transferring organoids to new culture conditions to support continued growth. This step helps maintain quality and uniformity of the organoids over time.
- **Quality Assurance (QA):** The activities designed to ensure that all aspects of organoid biobanking meet defined quality standards, ensuring reliability, consistency, and ethical compliance.
- **Quality Management System (QMS):** A framework for managing quality within organoid biobanking, including policies, procedures, and responsibilities for maintaining high standards.
- **Regulatory Compliance:** Adherence to the laws, regulations, and guidelines that govern organoid biobanking practices, ensuring that all activities are conducted legally and ethically.
- **Reproducibility:** The ability to consistently achieve the same results across multiple iterations of the same process, ensuring reliability and standardization in organoid biobanking.
- **Risk Management:** The identification, assessment, and mitigation of potential risks in organoid biobanking activities, aimed at minimizing negative impacts and ensuring continuity.
- **Sample Integrity and Viability Testing:** Protocols and procedures for testing organoid samples after freezing, thawing, or prolonged storage to assess their biological and functional properties.
- **Standard Operating Procedures (SOPs):** Detailed guidelines that specify how tasks should be performed to ensure consistency and quality across all organoid biobanking activities.
- **Traceability:** The ability to document and track the history, application, and location of organoids and associated data from their collection through to their final disposition.

Source References:

1. ISO. ISO 20387:2018. Biotechnology — Biobanking — General requirements for biobanking. 2018.
2. ISO. ISO/TR 22758:2020. Biotechnology — Biobanking — Implementation guide for ISO 20387. 2020.
3. ISO. ISO 15189:2022. Medical laboratories — Requirements for quality and competence. 2022.
4. ISBER. ISBER Best Practices: Recommendations for Repositories. 5th edition. International Society for Biological and Environmental Repositories, 2023.
5. IARC. Common Minimum Technical Standards and Protocols for Biobanks Dedicated to Cancer Research. IARC Technical Publication No. 44. International Agency for Research on Cancer, 2017.
6. ISO/IEC. ISO/IEC 17025:2017. General requirements for the competence of testing and calibration laboratories. 2017.
7. AABB. Standards for Cellular Therapy Services. 12th edition. Association for the Advancement of Blood & Biotherapies, 2025. ISBN: 978-1-56395-523-5.
8. ISO. ISO 9001:2015. Quality management systems — Requirements. 2015.
9. NIST. NIST AI 600-1. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile. National Institute of Standards and Technology, 2024. DOI: 10.6028/NIST.AI.600-1.
10. ISO. ISO 13485:2016. Medical devices — Quality management systems — Requirements for regulatory purposes. 2016.